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Abstract 
Co-crystallization allows the manipulation of physical properties of a given compound 
without affecting its chemical behavior. The ability to predict hydrogen bonding interactions, 
provides means to the rational design of supramolecular architectures. It also makes it possible to 
select with a degree of accuracy, a few co-formers that have a high probability of forming co-
crystals with a compound of interest, instead of blindly screening against a large number of 
candidates.  
To study the effects of changing electronic environment on the ability to form co-crystals, 
five symmetric dioximes of different hydrogen bond donating ability were synthesized with 
different functional groups on the carbon α to the oxime moiety. It was shown that the 
supramolecular yield increase with the positive MEP value on the donor site. 
In order to further explore this relationship between calculated MEP values and 
supramolecular selectivity three asymmetric ditopic donors containing phenol carboxylic acid and 
aldoxime groups were screened against a series of asymmetric ditopic acceptors. Nine crystal 
structures show that the supramolecular outcome can be predicted according to Etter’s rules by 
ranking donors and acceptors according to calculated MEP values. 
To explore the possibility of using the same approach with other hydrogen bond donors, 
three asymmetric ditopic donor ligands containing cyanooxime groups were synthesized and 
screened against a series of asymmetric ditopic acceptors. Nine out of ten times the supramolecular 
outcome could be predicted by MEP calculations 
1-deazapurine exists in two tautomeric forms (1H and 3H) in aqueous solution, which have 
very different hydrogen bonding environments. The 3H tautomer forms a self-complementary 
dimer involving a donor and an acceptor site leaving a second acceptor site vacant. In order to 
stabilize this tautomer the molecule was screened against a of series hydrogen and halogen bond 
donors. Four out of five structures obtained showed 3H tautomer. The 1H tautomer is the geometric 
complement of urea. Therefore the molecule was screened against a series of N,N-diphenylureas 
and all five structures showed the 1H tautomer. 
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Chapter 1. Introduction 
1.1. Supramolecular chemistry 
Supramolecular chemistry is the chemistry of the intermolecular bond. It can be defined as 
the chemistry beyond the molecule1. It goes beyond the scope of molecular or covalent chemistry 
that deals with combining atoms with covalent bonds to form molecules, their properties and 
reactions. In supramolecular chemistry, weaker reversible interactions bring molecules together to 
form large aggregates or “supermolecules” 
 
Figure 1.1 Covalent synthesis vs. Supramolecular synthesis 
In the field of crystal engineering, the crystal engineer harnesses non-covalent interactions 
in order to rationally design and construct supramolecular aggregates. Unlike covalent chemistry, 
where many steps can be followed to get from reactant to product allowing the chemist a fair 
degree of control on how the atoms are brought together (Figure 1.1), most supramolecular 
reactions are single step processes and therefore a proper understanding is required of the 
underlying interactions in order to attain the desired aggregate. 
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1.1.1. Self-assembly 
Self-assembly is the spontaneous non-covalent association of two or more molecules under 
equilibrium conditions into stable well-defined aggregates2. As shown in Figure 1.2 the two 
molecules have come together in a specific manner in aqueous solution to form a large ordered 
structure. 
 
Figure 1.2 Self-assembly of a supramolecular tetramer3 
This type of self-assembly is due to preferences in forming supramolecular interactions or due to 
certain pairs of groups always forming non–covalent interactions to each other. This phenomenon 
is known as molecular recognition. 
1.1.2. Molecular recognition 
One interesting feature of non-covalent interactions is the high degree of selectivity 
involved. This is seen in biological systems where reversible non-covalent interactions facilitate 
aggregation whilst maintaining the dynamic nature required of biological function. For example 
the binding of an enzyme to its substrate (Figure 1.3)4 and the binding molecule to its specific 
receptor site and base pairing of nucleic acids all involve a great deal of specificity and all result 
from non-covalent interactions.  
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Figure 1.3 The highly specific enzyme-substrate interaction (lock and key mechanism). 
 
Molecular recognition was first observed by Emil Fisher in the selective binding of an 
enzyme to its substrate5. He suggested a lock and key mechanism where, as shown in Figure 1.3, 
the enzyme has a choice of three substrates but selectively binds to the substrate that is the correct 
geometric fit for its active site. In the words of J. M. Lehn, molecular recognition is “binding with 
a purpose”6  therefore these events need to be geometrically compatible and energetically favored 
in order to take place. In a competitive system consisting of multiple functional groups capable of 
non-covalent interactions, molecular recognition will result in some groups selectively binding to 
others. For example, in the multi-component crystal of iso-nicotinamide and carboxylic acids7 
there are three groups capable of hydrogen bonding, a carboxylic acid group, an amide group and 
a pyridyl site. As shown in Figure 1.4, the acid selectively binds to the pyridyl nitrogen atom and 
the amide to itself in both cases with different acids. 
Enzyme Substrates 
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Figure 1.4 Primary hydrogen bonding interactions between isonicotinamide with (a) 3-
nitrobenzoic acid and (b) 4-chlorobenzoic acid7 
 
1.2. The Hydrogen bond 
Of all the non-covalent interactions, the hydrogen bond has received most attention. The 
idea was first introduced by Latimer and Rodebush8 in 1920 and later brought to attention by 
Pauling in 19399.The simplest definition for a hydrogen bond is “a weak electrostatic chemical 
bond which forms between covalently bonded hydrogen atoms and a strongly electronegative atom 
with a lone pair of electrons10” The current IUPAC definition for a hydrogen bond is as follows 
“The hydrogen bond is an attractive interaction between a hydrogen atom from a molecule or a 
molecular fragment X–H in which X is more electronegative than H, and an atom or a group of 
atoms in the same or a different molecule, in which there is evidence of bond formation.”11 The X-
H group is known as the hydrogen bond donor and the group it binds to is known as a hydrogen 
bond acceptor (Figure 1.5). 
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Figure 1.5 A schematic representation of a typical hydrogen bond 
The actual attractive forces behind hydrogen bonding has been subjected to a lot of debate. Some 
consider the hydrogen bond to be strong and directional dipole-dipole interaction12. Others 
considered hydrogen bond to comprise of an electrostatic component and a covalent component 
13. 
Examples of co-operativity14 and resonance stabilized hydrogen bonds15,16 indicate that 
there may be some covalent nature involved in hydrogen bonding. Experimental evidence for 
covalent behavior in hydrogen bonding was provided in a Compton scattering experiment on ice 
which show a periodic shift in hydrogen bond length corresponding to distances of 1.72 and 2.85 
Å, which are similar to the hydrogen bond length and O-O distance, respectively17. Energy 
decomposition studies however, show the electrostatic contribution to be the dominant factor in 
hydrogen bonding18. 
 
Hydrogen bonds are of utmost importance in biological systems. It is the main driving force behind 
many substrate-receptor interactions. In addition it plays a vital role in the three dimensional 
structure of proteins and in the structure of nucleic acids19(Figure 1.6). 
 
Figure 1.6 Hydrogen bonded base pairing of DNA 
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Table 1.1 gives a comparison of energies of hydrogen bonds compared to other 
intermolecular interactions. Apart from ionic and ion dipole interactions, hydrogen bonds can be 
classified as one of the stronger non-covalent interactions. Unlike ionic or ion-dipole interactions, 
hydrogen bonds are directional20, which makes them ideal candidates in the design of 
supramolecular architectures. Hydrogen bonds are classified as strong, medium and weak 
hydrogen bonds21. This property arises from the two species (hydrogen bond donor and hydrogen 
bond acceptor) between which the bond is formed. 
 
Table 1.1 comparison of energies for different molecular interactions21 
Interaction Strength/kJmol-1 Example 
Ion-ion 200 - 300 
Tetrabutylammonium 
chloride 
Ion-dipole 50 – 200 Sodium [15]crown-5 
Dipole-dipole 5 - 50 Acetone 
Strong hydrogen bond 60 - 120 HF 
Medium hydrogen bond 16 – 60 Carboxylic Acids, DNA/RNA 
Weak Hydrogen bond < 12 C-H•••O 
Halogen bond22 5 - 180 I-•••I2 
Cation-π 5 - 80 K+ in benzene 
π – π 0 - 50 Benzene  
Van der Waals 
< 5 kJmol-1 variable depending 
on surface area 
Argon 
 
1.2.1. Selectivity in hydrogen bonding and Etter’s rules 
As mentioned above, hydrogen bonds are highly selective intermolecular interactions and 
the driving force behind molecular recognition, therefore, to better understand molecular 
recognition a better understanding of the selectivity involving hydrogen bonding is required.  
The first comprehensive study on hydrogen bond selectivity was carried out by Etter et. al. 
Analysis of the Cambridge Structural Database for groups of neutral molecules with sterically 
accessible hydrogen bonding groups allowed Etter and co-workers to determine the possible 
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preferences for individual functional groups in terms of selectivity and patterns of aggregation in 
solids. They also developed a method to depict these aggregation patterns called “graph set 
notations” (Figure 1.7). 
 
Figure 1.7 Graph set notation 
 
Based on their observations, Etter and co-workers proposed a set of guidelines23,24 on the 
selectivity of hydrogen bonding. These guidelines are currently known as Etter’s rules the first 
three of which are shown below. 
1. All good proton donors and acceptors are used in hydrogen bonding 
2. If a six-membered intramolecular hydrogen bond can form, it will usually do so in 
preference to forming intermolecular hydrogen bonds 
3. The best proton donors and acceptors remaining after intramolecular hydrogen-bond 
formation, form intermolecular hydrogen bonds to one another 
 
1.3. Co-crystals 
The definition of the term co-crystal has been subjected to some debate25,26. The purpose 
of co-crystallization is to combine two or more different species in the solid state. A co-crystal can 
be defined as a structurally homogeneous crystalline material that contains two or more neutral 
building blocks that are present in definite stoichiometric amounts where all the building blocks 
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are solids at ambient conditions.27 Multicomponent systems such as solvates and clathrates are not 
considered to be co-crystals under this definition.  
 
Figure 1.8 Recrystallization vs co-crystallization 
Co-crystallization is not to be confused with recrystallization which results in like molecules 
binding to each other(Figure 1.8). This type of aggregation is more common due to the “selfish” 
nature of molecules and is commonly used as a method of purification. In order to synthesize 
multicomponent solids or co-crystals, the natural propensity for recrystallization needs to be 
overcome. A proper understanding of the underlying interactions enables the supramolecular 
chemist to overcome this barrier to design and construct multi-component architectures. 
1.3.1. Importance in industry 
Bringing different molecules together in the solid state using inter-molecular interactions 
does not affect the chemical properties of any of the constituents as no covalent modification takes 
place. Using the tools of crystal engineering it is possible to tune the physical properties such as 
melting point28, solubility28 hygroscopicity29 of a given compound without affecting its intrinsic 
chemical properties or activity.  
In the pharmaceutical industry for example a significant number (41%) of pharmaceutical 
ingredients fail to make it to the market due to poor physical properties (Figure 1.9). As co-
crystallization does not affect the chemical nature of the drug, it is conceivable that a co-crystal of 
the said compound can be synthesized that does not contain any of the undesired physical 
properties. 
9 
 
 
Figure 1.9 Reasons why active pharmaceutical compounds do not make it to the market30 
This has in recent times made certain areas such as pharmaceuticals28,31, agrochemicals32, 
non-linear optics33, explosives34, and organic semiconductors35 look to supramolecular chemistry 
for answers. 
The current methods for identifying possible co-crystal formers involves screening the 
molecule of interest against a series of potential co-crystal formers and analyzing them for the 
formation of co-crystals. This type of blind large-scale screening is time-consuming and costly. A 
proper understanding of the underlying supramolecular interactions makes it possible to pick the 
best coformers based on the functionalities present on the molecule of interest. It also makes it 
possible to custom design the supramolecular architecture in order to attain desired physical 
properties. 
1.3.2. Visualizing molecular interactions 
Many different methods such as IR spectroscopy, powder X-day diffraction and NMR 
based methods can be used to detect the formation of co-crystals. Even though these methods 
provide evidence for co-crystal formation, they provide little information as to the actual 
interactions responsible for the formation of the co-crystal. The exact molecular interactions taking 
place in solution are not easily observed due to the dynamic nature of these weak reversible 
interactions. The actual intermolecular interactions or the molecular recognition events responsible 
for the formation of co-crystals can be visualized through single crystal X-ray diffraction of the 
Poor bio-
pharmacutical 
properties
40%
Toxicity
22%
Lack of efficacy
32%
Market reasons
6%
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said co-crystal. This however, requires a crystal of sufficient quality for X-ray diffraction to be 
grown which may prove difficult at times. 
Experimental methods such as NMR binding studies or isothermal titration calorimetry are 
used to experimentally determine the binding constants for hydrogen bonding36. The ability to 
perform such analyses is system specific. In addition experimentally determining the binding 
constants for hundreds of potential co-crystal formers is time consuming and expensive and 
therefore unfeasible in an industrial environment37. 
1.4. Predicting molecular recognition 
The direct use of pKa based methods have proven effective in some studies as predictors for 
hydrogen bond donor ability, donors with lower pKa values (more acidic) are considered to be 
better hydrogen bond donors. There are many examples in literature where the supramolecular 
outcome has been successfully predicted based on pKa values38. As shown in Figure 1.10, a ternary 
co crystal was designed with the asymmetric ditopic acceptor iso-nicotinamide and two aromatic 
acids, where 3,5-dinitrobenzoic acid with the lower pKa of 2.8 selectively binds to the pyridyl 
nitrogen, which is the stronger acceptor of iso-nicotinamide and 3-methylbenzoic acid (pKa = 4.3) 
binds to the weaker amide group.  
 
Figure 1.10 A 1:1:1 ternary cocrystal of  3,5-dinitrobenzoic acid : iso-nicotinamide : 3-
methylbenzoic acid designed based on pKa39 
 
This method is effective if limited to a single class of compound upon comparing in the case of 
phenols and thiophenols, thiophenol has a pKa of 6.61 which is considerably lower than that of 
phenol (pKa=9.86), which indicates that thiourea should be a better hydrogen bond donor. 
Experimentally however, phenols have significant hydrogen bond donor ability40 and are 
commonly used as hydrogen bond donors whereas thioureas hardly exhibit any hydrogen bond 
donor ability41,. 
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1.5. Predicting hydrogen bonding through calculated molecular electrostatic 
potential surfaces. 
 
Assuming that hydrogen bonds are mostly electrostatic a computational method was 
developed by Hunter et. al.. where, they attempt to explain hydrogen bonding based on 
electrostatics. Where the association constant (K) of two simple molecules can be treated as  shown 
in Equation 1.1 where, αH2 and βH2  are functional group constants that relate to the hydrogen bond 
donor and hydrogen-bond acceptor properties. This is equivalent to the expression of the 
electrostatics of the hydrogen bonding interaction, where the free energy of interaction changes 
with the product of the positive charge on the hydrogen-bond donor (αH2) and the negative charge 
on the hydrogen bond acceptor (βH2) 
    
Figure 1.11 Molecular electrostatic potential surfaces calculated from SPARTAN 
 
log K = c1 αH2 βH2  + c2     1.1 
 
The charge parameter can be determined by a molecular electrostatic potential surface 
constructed around the molecule through a semiemperical AM1 calculation (Figure 1.11) where 
the maxima (shown in blue) correspond to the charges on the donors and the minima (shown in 
red) correspond to the charge on the acceptors (equation 1.2 and 1.3)42.  
 
α = Emax/52 kJmol-1 = 4.1 (αH2 + 0.33)    1.2 
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β = -Emin/52 kJmol-1 = 10.3 (βH2 + 0.06)   1.3 
 
Even though these equations were designed to explain hydrogen bonding with solvents. 
These α and β values can be used for the comparison and ranking of hydrogen bond donor and 
acceptor groups respectively.  
The values obtained have no relation to actual charge or any other thermodynamic 
parameters on the molecule. Predictions based on calculated values have been shown to be 
consistent with experimental observations42 and therefore can be used as a scale of comparing 
different molecules and functional groups. This type of prediction provides a cheap and reliable 
means to postulate the hydrogen bonding abilities and preferences of different molecules in order 
to select the best candidates for experimental screening. 
1.6. Goals 
In order to construct multi-component non-covalently bound architectures, a proper 
understanding of the underlying interactions is required. Computational tools provides a 
convenient means to rank and compare different donor and acceptor groups. Little parallel 
experimental exploration exists to validate predictions based on calculated values.  
The goal of this thesis is to  
 Study the effects of covalent modification on the supramolecular behavior of oximes 
 Synthesize asymmetric ditopic donors comprising the strong hydrogen bond donor 
groups phenol, carboxylic acid, cyanooxime and aldoximes in order to rank these 
hydrogen bond donor functionalities by the synthesis and analysis of co-crystals. 
 Compare predictions based on computational results with experimental results to 
explore their validity. 
 Use the tools of crystal engineering to design supramolecular agents that can isolate 
two tautomeric forms of 1-deazapurine in the solid state. 
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Chapter 2. Fine-tuning the hydrogen bond donor ability of 
oximes 
2.1. Introduction 
2.1.1. Oximes 
Molecules containing an oxime functionality have found importance in pharmaceutical1,2 
(Figure 2.1 a), agrochemical3, organometallic4,5 (Figure 2.1 b) and biological materials6 (Figure 2.1 
c). In most of these areas, function is related to the reactivity and structure of the oxime moiety. 
 
 
Figure 2.1  (a) Reactivation of acetylcholine esterase inhibited by a nerve agent with 
pralidoxime.7 (b) Platinum(II)oximes – potential anti-cancer drug4 (c) Perillartine, an 
artificial sweetener6. 
 
The oxime group contains a hydrogen bond donor site and two acceptor sites (Figure 2.2) that 
can have potential applications in supramolecular chemistry.  
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Figure 2.2 Hydrogen bonding sites on the oxime moiety 
As explained in Chapter 1 the supramolecular chemist can modify the physical properties 
of a certain species without altering its chemical properties by synthesizing multi component solids 
or co-crystals with neutral organic molecules. Hydrogen-bond donors like carboxylic acids8, 
hydroxyl groups9, and amides form robust reliable supramolecular synthons that can be used to 
engineer such multicomponent solids or co-crystals with various acceptors10. 
 
A CSD survey of the oxime moiety yields 573 structures that exhibit a diverse spread of 
connectivities and synthons. Oxime-oxime homomeric interactions result in dimeric, catemeric or 
chain type structures11 as shown in Figure 2.3 (a) and (b). They also form heteromeric interactions, 
complementary two point dimers with acids and amides, single point interactions with the carbonyl 
groups and aromatic N atoms of heterocyclic molecules as shown in Figure 2.3 (c).  
 
Figure 2.3 Different binding modes of oximes (a) self-complementary two point homomeric 
dimer (b) Single-point homomeric interactions resulting in chains or catemers. (c) Most 
common heteromeric interactions. 
 
(c) 
 
 
(a)  
(b)  
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As shown in Figure 2.3, the oxime moiety is capable of a diverse array of supramolecular 
connectivities. Its ability to form reliable robust supramolecular synthons requires further 
exploration. As shown in Table 2.1, a CSD survey of neutral multi-component solids of different 
donor groups shows that compared to other hydrogen bond donor functionalities, very little has 
been published on the oxime moiety. 
Table 2.1 A CSD survey of multicomponent structures for each donor moiety 
 
    
Multi 
component 
solids 
1793 2184 2576 87 
 
The oxime group possesses a unique tunability that is not present in other hydrogen bond 
donors. By changing the group R, it is possible not only to change the donor ability of the –OH 
but also to alter the type of binding interaction. Most oximes form an O-H∙∙∙N homomeric 
interaction to itself resulting in either dimers (Figure 2.3(a)), chains or catemers (Figure 2.3(b)) 
but changing the R group can alter this behavior. 
 
 
Figure 2.4 Alternate binding interactions observed in (a) amideoximes (b) cyanooximes12 
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As shown in Figure 2.4, the amide oxime shows a secondary interaction (Figure 2.4 (a)) 
where the amide N-H group binds to the oxygen atom on the oxime moiety. Similarly the 
cyanooxime group does not show the typical oxime-oxime O-H…N interaction instead the O-H 
group binds to the CN on the cyanooxime (Figure 2.4 (b)) resulting in catemers. 
2.1.2. Predicting the supramolecular outcome 
To predict the supramolecular outcome it is necessary to establish a hierarchy of hydrogen 
bond donors and acceptors. A range of methods can be utilized for this purpose as the comparison 
here involves the same functionality such as pKa13, hydrogen bond acidity14 or molecular 
electrostatic potential calculations15,16. 
Since hydrogen bonding is mostly electrostatic in nature, we have chosen molecular 
electrostatic potential calculations to rank our hydrogen bond donors. Here we plot molecular 
electrostatic potential surfaces using AM1 calculations.  Donors are ranked by values of the 
maxima of the MEP surfaces plotted.  
   
Figure 2.5 Molecular electrostatic potential calculations 
 
2.1.3. Hypothesis 
We hypothesize that the hydrogen bond donor ability of oxime groups can be tuned by 
changing the R substituent. (Figure 2.6) The hydrogen bond donating ability of the ligands can be 
compared by the comparing the supramolecular yields17, or the frequency of co-crystal formation 
under similar reaction conditions. The supramolecular yield can be determined by screening 
donors against a selection of acceptors of different acceptor strengths. Stronger donors will exhibit 
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a higher frequency of co-crystal formation or supramolecular yield, compared to weaker donor 
groups. 
 
Figure 2.6 Substitution of the R group with electron donating and electron withdrawing 
groups to tune the hydrogen bond donor ability of the donor site 
 
The goals of this chapter are to, 
 Synthesize five symmetric aromatic dioximes. (Figure 2.7)  
 Perform molecular electrostatic potential calculations on the five synthesized donors and 
the 20 acceptors 
 
Figure 2.7 Library of symmetric ditopic oximes 
 Screen the dioximes against a library of 20 monotopic, symmetric ditopic and symmetric 
tritopic acceptors.(Figure 2.8) 
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Figure 2.8 Library of hydrogen bond acceptors used in this study 
 
 Establish if it is possible to correlate the MEP values of each oxime with its ability to form 
co-crystals.  
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2.2. Experimental 
2.2.1. Synthesis of dioximes 
All chemicals were purchased from Aldrich, Fisher Scientific and used without further 
purification, Melting points were determined on a GallenKamp melting point apparatus and are 
reported uncorrected. 1H and 13C NMR spectra were recorded on a Varian Unity plus 400 MHz 
spectrometer in DMSO-d6. Compounds were prepared for infrared spectroscopic (IR) analysis on 
a ZnSe ATR crystal. 
 
2.2.1.1. Synthesis of 1,4-benzenedicarboxaldehyde dioxime, di(H)ox 
 
Terepthalaldehyde (2.00 g, 14.9 mmol) and NH2OH.HCl (1.24 g 17.9 mmol) were ground 
together to a fine powder with a mortar and pestle. NaOH pellets (0.72 g, 17.9 mmol) were crushed 
and ground into the mixture. Two drops of methanol were added and grinding was continued for 
two more minutes. The mixture was allowed to stand for ten minutes, then ground again for two 
minutes. The absence of starting material was confirmed via TLC. The solid was dissolved in 200 
ml of a 1:1 mixture of water and ethanol. The ethanol was removed under reduced pressure to 
isolate an off white solid. (2.2 g, 89.9%) m.p. 218 -220 0C (lit. 219 -220 0C)11  1H NMR (400 MHz, 
DMSO-d6)  ppm 7.61 (4 H, s), 8.14 (2 H, s), 11.36 (2 H, s) IR: ν 1623 cm-1 (C=N), ν 3143 cm-
1(O-H), ν 962 cm-1(O-N) 
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2.2.1.2. Synthesis of 1,4-diacetylbenzene dioxime, di(CH3)ox 
 
1,4-diacetylbenzene (2.00 g, 12.3 mmol) and NH2OH.HCl  (1.03 g 14.8 mmol) were 
ground together to a fine powder with a mortar and pestle. NaOH pellets (0.59 g, 14.8 mmol) were 
crushed and ground into the mixture. Two drops of methanol were added and grinding was 
continued for two more minutes. The mixture was allowed to stand for ten minutes, and ground 
again for two minutes. The absence of starting material was confirmed via TLC. The solid was 
dissolved in 200 ml of a 1:1 mixture of water and ethanol. The ethanol was removed under reduced 
pressure to isolate a white solid. m.p. 165 - 170 0C (lit. 170 0C)11 1H NMR (400 MHz, DMSO-d6) 
 ppm 2.15 (6 H, s), 7.66 (4 H, s), 11.28 (2 H, s) IR: ν 1660 cm-1 (C=N), ν 3244 cm-1(O-H), ν 
921 cm-1(O-N) 
2.2.1.3. Synthesis of N'1,N'4-dihydroxyterephthalimidoyl dichloride, di(Cl)ox 
 
di(H)ox (0.75 g 0.0045 mol) was dissolved in 250 ml CHCl3. N-chlorosuccinimide (2.7 g 
0.020 mol) was added to the stirring suspension with a few drops of pyridine. The mixture was 
allowed to stir at room temperature for 24 hours. Once no starting material was observed by TLC 
the reaction mixture was washed with 10% NaHCO3, water and brine. The organic layer was dried 
over MgSO4, the solvent was removed under reduced pressure to yield a brown solid. (0.68 g 
65.0%) m.p. 145 - 150 0C (lit. 177.5 -179 0C)18 1H NMR (400 MHz, DMSO-d6)  ppm 7.89 (4 H, 
s), 12.63 (2 H, s) IR: ν 1686 cm-1 (C=N), ν 3403 cm-1(O-H), ν 991 cm-1(O-N) 
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2.2.1.4. Synthesis of 2,2'-(1,4-phenylene)diacetonitrile 
 
α,α’-Dichloro-p-xylene (2.00 g  11.4 mmol) was dissolved in 150 ml of acetonitrile. NaCN 
(2.23 g  45.6 mmol) was added to the stirring solution and stirred overnight at 50 0C, until no 
starting material was observed by TLC, the acetonitrile was removed under reduced pressure. The 
residue was dissolved in 200 ml ethyl acetate and washed repeatedly with water and brine. The 
organic layer was then dried over MgSO4 and ethyl acetate removed under reduced pressure to 
yield pure product. (1.42 g 80.0%) m.p. 94 -98 0C (lit 96 - 98 0C)19 1H NMR (400 MHz, DMSO-
d6)  ppm 7.89 (4 H, s), 12.63 (2 H, s) 
2.2.1.5. Synthesis of N'1,N'4-dihydroxyterephthalimidoyl cyanide, di(CN)ox 
 
2,2'-(1,4-Phenylene)diacetonitrile (1.2 g .0077 mol) was dissolved in 50 ml of methanol 
and poured into a solution of NaOH (10 g) in 300 ml of methanol. This was allowed to stir for 2 
hours. MeONO gas was generated by pouring a solution of 16 ml conc. H2SO4 in 32 ml of water 
dropwise into a solution of NaNO2 (10 g, 0.145 mol) in 100 ml water and 50 ml methanol. The gas 
generated was bubbled through the solution of 2,2'-(1,4-phenylene)diacetonitrile over a period of 
30 min. Once the bubbling was complete, the solution was stirred at room temperature for 48 
hours. Methanol was removed under reduced pressure. The resulting solid was dissolved in 60 ml 
of water and slowly acidified with 6 M HCl in an ice bath. The resulting yellow solid was filtered 
off.  (1.12 g, 68%) m.p. 170 0C dec. (lit 192-194 0C)20 1H NMR (400 MHz, DMSO-d6) d ppm 7.86 
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(4 H, s), 14.07 (2 H, br. s.) IR: ν 2244 cm-1 (C≡N), 1427 cm-1 (C=N), ν 3274 cm-1(O-H), ν 973 
cm-1(O-N) 
2.2.1.6. Synthesis of N'1,N'4-dihydroxyterephthalimidamide, di(NH2)ox 
 
1,4-Dicyanobenzene (0.50 g , 0.039 mol) was dissolved in 100 ml ethanol with 
NH2OH.HCl (1.380 g, 0.097 mol). 30 ml of a solution of K2CO3 (1.35 g, 0.097 mol) in water was 
then added. The solution was refluxed overnight and monitored by TLC until no starting material 
remained. The solvent was removed and the white solid was washed with water.(0.45 g, 60%) m.p. 
215 0C dec. (lit. 210 0C dec.)11 1H NMR (400 MHz, DMSO-d6)  ppm 5.84 (5 H, br. s.), 7.66 (4 
H, s), 9.69 (2 H, s) IR: ν 1646 cm-1 (C=N), ν 3443 cm-1(O-H), ν 923 cm-1(O-N) 
2.2.2. Conditions used in the co-crystallization. 
2.2.2.1. Synthesis of 1,4-benzenedicarboxaldehyde, 1,4-dioxime 4-picolyl-N-oxide(1:2), 
di(H)ox:4po 
di(H)ox (0.010g, 0.061 mmol) was ground together with 4po (0.007 g, 0.061 mmol) with 
a few drops of methanol until a homogenous mixture was obtained. The solid obtained was 
dissolved in 3 ml of methanol with heat and allowed to stand at room temperature for slow 
evaporation. Colorless prisms were obtained in two weeks. (m.p. 116 - 120 0C) 
2.2.2.2. Synthesis of N'1,N'4-dihydroxyterephthalimidoyl cyanide 4-picolyl-N-
oxide(1:1), di(CN)ox:4po 
di(CN)ox (0.010g, 0.047 mmol) was ground together with 4po (0.005 g, 0.047 mmol) with 
a few drops of methanol until a homogenous mixture was obtained. The solid obtained was 
dissolved in 4 ml of methanol with heat and allowed to stand at room temperature for slow 
evaporation. Yellow plates were obtained in 10 days. (m.p. 230 0C dec) 
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2.2.2.3. Synthesis of N'1,N'4-dihydroxyterephthalimidoyl cyanide 4-benzoylpyridine 
(1:2), di(CN)ox:4bp 
di(CN)ox (0.010g, 0.047 mmol) was ground together with 3bp (0.009 g, 0.047 mmol) with 
a few drops of methanol until a homogenous mixture was obtained. The solid obtained was 
dissolved in 4 ml of methanol with heat and allowed to stand at room temperature for slow 
evaporation. Colorless plates were obtained in 10 days. (m.p. 98 - 102 0C) 
2.2.2.4. Synthesis of N'1,N'4-dihydroxyterephthalimidoyl cyanide 4-benzoylpyridine 
(1:2), di(CN)ox:3bp 
di(CN)ox (0.010g, 0.047 mmol) was ground together with 3bp (0.009 g, 0.047 mmol) with 
a few drops of methanol until a homogenous mixture was obtained. The solid obtained was 
dissolved in 4 ml of methanol with heat and allowed to stand at room temperature for slow 
evaporation. Yellow plates were obtained in 14 days. (m.p. 95 - 100 0C) 
2.2.2.5. Synthesis of N'1,N'4-dihydroxyterephthalimidamide DMSO (1:2), 
di(NH2)ox:DMSO 
di(NH2)ox (0.010g, 0.051 mmol) was ground together with bpe (0.009 g, 0.051 mmol) 
with a two drop of methanol until a homogenous mixture was obtained. The solid obtained was 
dissolved in 1 ml of DMSO with heat and allowed to stand at room temperature for slow 
evaporation. Colorless plates were obtained in 30 days. (m.p. 210 0C dec.) 
2.2.3. Semi empirical AM1 calculations 
The molecular structures of the five donors and the 20 acceptors were constructed using Spartan 
’06 (Wavefunction, Inc. Irvine, CA). All molecules were optimized using Semi-empirical AM1 
with the maxima and minima in the electrostatic potential surface (0.002 e/au isosurface) 
determined using a positive point charge in the vacuum as a probe. 
2.2.4. Solvent drop grinding experiments 
0.01 g of the donor was ground together with the acceptor in a 1:1 molar ratio on a well 
plate with a drop of methanol. After two minutes of grinding the solid was analyzed via infra-red 
spectroscopy. 
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2.3. Results 
2.3.1. Molecular electrostatic potential calculations 
AM1 Calculations were carried out on the five donors (Table 2.2) and the 20 acceptors 
(Table 2.3) with Spartan 06. 
Table 2.2 Calculated molecular electrostatic potential values for the five donors 
Donor 
di(NH2)ox di(CH3)ox di(H)ox di(Cl)ox di(CN)ox 
     
MEP/kJmol-1 124 140 144 163 185 
 
The calculated molecular electrostatic potential values for the oxime proton changes 
significantly with different substituents. Electron donating groups decrease the MEP value and 
electron withdrawing groups increase the MEP value. 
Table 2.3 Calculated molecular electrostatic potential values for the 20 acceptors 
  Name MEP(AM1)/kJmol-1 
N-Oxides 
3po 3-Picolyl-N-oxide -313 
4po 4-Picolyl-N-oxide -312 
bpo 4,4'-Bipyridine-bis-N-oxide -287 
Benzimidazoles 
dbim 
1,4-Bis((1H-benzo[d]imidazol-1-
yl)methyl)benzene 
-295 
tbim 
1,3,5-Tris((1H-benzo[d]imidazol-1-
yl)methyl)benzene 
-289 
Bipyridyls 
bpe 1,2-Bis(4-pyridyl)ethane -285 
bpe2 (E)-1,2-Di(pyridin-4-yl)ethene -285 
dpp 4,4'-Trimethylenedipyridine -281 
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bp 4,4'-Bipyridine -269 
Pyridine 
3bp 3-Benzoylpyridine -271 
4bp 4-Benzoylpyridine -268 
4pp 4-Phenylpyridine -267 
25dbp 2,5-Dibromopyridine -257 
dcp 3,5-Dichloropyridine -232 
35dbp 3,5-Dibromopyridine -230 
Pyrazoles 
dmpy 
1,4-Bis((3,5-dimethyl-1H-pyrazol-1-
yl)methyl)benzene 
-254 
dpy 1,4-Bis((1H-pyrazol-1-yl)methyl)benzene -248 
bdpy 
1,4-Bis((4-br-3,5-dime-1H-pyrazol-1-
yl)methyl)benzene 
-237 
Pyrazines 
mpz 2,3,5,6-Tetramethylpyrazine -273 
pz Pyrazine -224 
  
Calculated MEP values for the acceptors show a wide spread of AM1 values which can be 
roughly grouped according to the class of compound as N-oxides > benzimidazoles > bypyridyls 
> pyridines > pyrazoles > pyrazine. 
 
2.3.2. Solvent drop grinding experiments 
Table 2.4 contains the summarized results obtained through solvent drop grinding. The 
donors are arranged according to increasing MEP charge from left to right, and the acceptors are 
arranged according to decreasing negative MEP value from top to bottom.  
It can be observed in table 2.4, that there is a higher incidence of positive hits at higher 
positive MEP value of the donors and higher negative MEP values of the acceptors. 
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Table 2.4 Supramolecular yields based on IR spectroscopy 
 Name di(NH2)ox di(CH3)ox di(H)ox di(Cl)ox di(CN)ox 
MEP(AM1)  124 140 144 163 185 
-313 3po √ √ √ √ √ 
-312 4po √ √ √ √ √ 
-295 Dbim - √ √ √ √ 
-289 Tbim - √ √ √ √ 
-287 Bpo √ √ √ √ √ 
-285 Bpe √ √ √ √ √ 
-285 bpe2 - √ √ √ √ 
-281 dpp √ √ √ √ √ 
-273 mpz - - √ √ √ 
-271 3bp - - √ √ √ 
-269 bp √ √ √ √ √ 
-268 4bp - - √ √ √ 
-267 4pp - √ √ √ √ 
-257 25dbp - - - - √ 
-254 dmpy - √ √ √ √ 
-248 dpy - - - √ √ 
-237 bdpy - - - √ √ 
-232 dcp - - - - √ 
-230 35dbp - - - - √ 
-224 pz - - - - √ 
Number of positive hits 6/20 11/20 14/20 16/20 20/20 
Supramolecular yield 30% 55% 70% 80% 100% 
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2.3.2.1. Crystal structure of 1,4-Benzenedicarboxaldehyde dioxime 4-picolyl-N-
oxide(1:2), di(H)ox:4po 
The crystal structure of di(H)ox:4po contains one molecule of di(H)ox and two molecules 
of 4-picoline-N-oxide. The supermolecule is constructed through O-H∙∙∙O hydrogen bonds 
between the O-H of the oxime and the 4-picolyl-N-oxide oxygen atom O17∙∙∙O21, 2.644(2) Å, 
forming a zero dimensional trimer. (Figure 2.9) The two acceptor sites on the oxime moiety, 
showed no hydrogen-bonding activity. 
 
 
Figure 2.9 The supramolecular trimer in the 1:1 binary co-crystal of di(H)ox:4po 
2.3.2.2. Crystal structure of N'1,N'4-dihydroxyterephthalimidoyl cyanide, 1,4-dioxime 4-
picolyl-N-oxide(1:1), di(CN)ox:4po 
The crystal structure of di(CN)ox:4po contains one molecule di(CN)ox and one molecule 
of 4-picoline-N-oxide. The supermolecule is constructed through O-H∙∙∙O hydrogen bonds 
between the O-H of the oxime and the 4-picolyl-N-oxide oxygen atom O31∙∙∙O21, 2.591(3) Å, the 
N-oxide oxygen binds to two oxime O-H groups forming a one dimensional chain.(Figure 2.10) 
The two acceptor sites on the oxime moiety, showed no hydrogen-bonding activity in this co-
crystal. 
 
Figure 2.10 The infinite chain in the 1:1 binary co-crystal of di(CN)ox:4po 
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2.3.2.3. Crystal structure of N'1,N'4-dihydroxyterephthalimidoyl cyanide, 1,4-dioxime 4-
benzoylpyridine (1:2), di(CN)ox:4bp 
The crystal structure of di(CN)ox:4bp contains one molecule di(CN)ox and two molecules 
of 4-benzoylpyridine. The supermolecule is constructed through O-H∙∙∙N hydrogen bonds 
between the O-H of the oxime and the 4-picolyl-N-oxide oxygen atom O17∙∙∙N21, 2.714(2) Å, 
forming a zero dimensional trimer.(Figure 2.11) The two acceptor sites on the oxime and the 
carbonyl oxygen on the acceptor, showed no hydrogen-bonding activity. 
 
Figure 2.11 The supramolecular trimer in the 1:2 binary co-crystal of di(CN)ox:4bp 
2.3.2.4. Crystal structure of N'1,N'4-dihydroxyterephthalimidoyl cyanide, 1,4-dioxime 3-
benzoylpyridine (1:2), di(CN)ox:3bp 
The crystal structure of di(CN)ox:3bp contains one molecule di(CN)ox and two molecules of 3-
benzoylpyridine. The supermolecule is constructed through O-H∙∙∙N hydrogen bonds between the 
O-H of the oxime and the 4-picolyl-N-oxide oxygen atom O17∙∙∙N21, 2.673(4) Å, forming a zero 
dimensional trimer.(Figure 2.12) The two acceptor sites on the oxime and the carbonyl oxygen on 
the acceptor, showed no hydrogen bonding activity in this structure. 
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Figure 2.12 The supramolecular trimer in the 1:2 binary co-crystal of di(CN)ox:3bp 
2.3.2.5. Crystal structure of N'1,N'4-dihydroxyterephthalimidamide, DMSO (1:2), 
di(NH2)ox:DMSO 
The crystal structure of di(NH2)ox:DMSO contains one molecule of di(NH2)ox and two 
molecules of DMSO. The supermolecule is constructed through an oxime-oxime dimer with O-
H∙∙∙N hydrogen bonds between the O-H and the nitrogen atom on the oxime O17∙∙∙N17, 2.743(3) 
Å, and the NH2 group picks up two DMSO molecules O1S∙∙∙N18, 3.004 (3) Å, O1S∙∙∙N18, 3.007(3) 
Å resulting in a solvate.(Figure 2.13)  
 
Figure 2.13 The supramolecular tetramer in the 1:2 binary solvate of di(NH2)ox:DMSO 
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2.4. Discussion  
2.4.1. Synthesis 
The five dioximes were synthesized with little difficulty. Di(H)ox and di(CH3)ox were 
synthesized through a solid state approach21 where pure product was obtained in a matter of 
minutes. The same approach was not successful in the synthesis of di(NH2)ox where only partial 
reactivity was observed. No column chromatography was used to purify any of these products.  
2.4.2. Infra-red spectroscopy 
Infra-red spectroscopy was the tool of choice in detecting the formation or absence of a new 
supramolecular species. Typically, hydrogen bonding in this type of screen can be easily detected 
by the O-H∙∙∙N interaction which provides the unmistakable broad stretches in the 1,900 cm-1 and 
2,500cm-1 13(Figure 2.14).  
 
Figure 2.14 The IR spectrum of the 1:1 grind of di(CN)ox:dbim clearly showing both O-
H∙∙∙N stretches at 1862 cm-1 and 2467 cm-1. 
In this study it was observed that with both donors and acceptors with lower MEP values that 
this stretch was not observed. Evidence of supramolecular interaction was still observed by the 
shift of the C=N stretch around 1660 cm-1 and the C≡N stretch around 2240 cm-1 in the case of 
cyanooximes. For example the C=N stretch of di(H)ox (1,4-Benzenedicarboxaldehyde, 1,4-
dioxime) at 1623 cm-1 shifts to 1603 cm-1 after it was ground with dbim (1,4-bis((1H-
benzo[d]imidazol-1-yl)methyl)benzene), Figure 2.15. Similarly, the C=N stretch is observed at 
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1615 cm-1 in the co-crystal di(H)ox:dbim which proves that this shift is indicative of the formation 
of a co-crystal. 
 
Figure 2.15 The IR spectra of di(H)ox and the 1:1 grind of di(H)ox and dbim 
2.4.3. The effect of the MEP values and pKa on supramolecular yield 
pKa has commonly been used to rank hydrogen bond donor ability13,22. The hierarchy of 
donors established based on pKa values matches that established via calculated MEP values. The 
combined results of the grinding experiments clearly show a trend between the calculated MEP 
values of the oximes and the supramolecular yield as shown in Table 2.5. The donor with the 
lowest MEP value (di(NH2)ox) exhibits the lowest supramolecular yield and di(CN)ox with the 
highest MEP value exhibit a 100% supramolecular yield. These observations present the 
possibility of increasing the supramolecular yields by increasing the MEP potential value of the 
donor sites via covalent modification. 
Table 2.5 The effect of the MEP values and pKa on supramolecular yield 
Donor di(NH2)ox di(CH3)ox di(H)ox di(Cl)ox di(CN)ox 
MEP/kJmol-1 124 140 144 163 185 
pKa23 14.43 10.97 10.27 9.70 7.47 
Supramolecular yield 30% 55% 70% 80% 100% 
 
 
7
4
8
.5
0
7
5
7
.5
7
7
7
0
.5
8
7
9
5
.2
9 8
2
1
.0
9
8
5
2
.5
9
9
6
2
.2
0
9
7
6
.0
2
1
1
1
1
.6
9
1
2
1
2
.8
3
1
2
9
5
.0
3
1
4
0
6
.5
3
1
4
5
4
.2
3
1
4
7
9
.6
7
1
5
1
7
.1
0
1
5
4
0
.8
9
1
6
2
3
.4
3
1
7
5
4
.6
4
1
8
9
8
.8
9
1
9
3
4
.5
22
3
6
3
.7
2
2
7
5
9
.7
5
2
8
7
3
.3
4
2
9
8
3
.1
1
3
0
5
4
.8
43
1
4
3
.6
5
*kedal
 65
 70
 75
 80
 85
 90
 95
 100
%
T
8
3
0
.0
0
8
5
2
.7
9 9
4
1
.8
4
9
7
0
.2
5
1
0
0
9
.5
3
1
0
3
7
.5
6
1
0
6
8
.1
8
1
1
0
9
.8
5
1
2
1
0
.9
2
1
2
9
2
.5
7
1
3
0
9
.2
6
1
4
1
7
.2
7
1
4
5
5
.6
7
1
5
1
5
.1
5
1
5
5
6
.6
0
1
6
0
3
.0
6
1
9
3
7
.9
4
2
7
3
3
.4
5
2
8
5
2
.1
6
2
9
4
2
.2
2
3
0
3
1
.0
7
3
1
2
1
.2
4
*KEDALSA6-GRIND
 30
 40
 50
 60
 70
 80
 90
 100
%
T
 1000   1500   2000   2500   3000  
Wav enumbers  (cm-1)
34 
 
The two supramolecular architectures to be expected in this study are zero dimensional 
trimers with the monotopic acceptors and one dimensional chains with the symmetric ditopic 
acceptors.(Figure 2.16) 
 
Figure 2.16 Expected supramolecular architectures (a) 1D chains (b) 0D trimers 
The structures obtained so far, exhibit the expected architectures. In the case of 4-picoline-N-oxide 
(4po) the N-oxide group contains two lone pairs and therefore can accommodate two hydrogen 
bonds. In the cases of di(H)ox:4po and di(CN)ox:4po, with 1,4-benzenedicarboxaldehyde 
dioxime (di(H)ox), the N-oxide (4po) acts as a single point acceptor as the oxime (1) picks up a 
single lone pair in di(H)ox:4po. In the case of N'1,N'4-dihydroxyterephthalimidoyl cyanide, 1,4-
dioxime (di(CN)ox) both lone pairs on 4po are picked up by cyanooxime molecules forming an 
infinite chain. 
  Another observation was that the two acceptor sites on the oxime moiety (Figure 2.2) 
showed no hydrogen bond activity in any of the co-crystals obtained. A CSD survey also confirms 
this trend where no oxime-oxime homomeric interactions were observed in the presence of 
sterically unhindered acceptor groups. Calculated AM1 values show the charge on the nitrogen 
atom on the cyanooxime moiety to be between 180-238 kJ/mol which is in the same range as the 
weaker acceptors in our screen that had a very low supramolecular yield. Therefore it seems that 
the donor selectively picks up the stronger acceptor. 
No co-crystals suitable for X-ray diffraction were obtained from N'1,N'4-
dihydroxyterephthalimidamide (di(NH2)ox) in solution experiments due to its low solubility 
which resulted in the oxime crashing out in all 20 cases. Using DMSO to improve solubility 
resulted in the formation of a single 1:2 solvate with DMSO where the oxime group formed an 
oxime-oxime dimer and the -NH2 group formed hydrogen bonds with the oxygen atom on DMSO 
instead of the oxygen atom on the oxime group (Figure 2.4 (a)). No crystals suitable for X-ray 
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diffraction were obtained with N'1,N'4-dihydroxyterephthalimidoyl dichloride (di(Cl)ox) as the 
ligand decomposed over  time resulting in an opaque solution/solid. 
2.5. Conclusions 
The molecular electrostatic potential value of the oxime moiety can be tuned by altering 
the R substituent (Figure 2.4) where, the donor ability increases with the electron withdrawing 
substituents and is reduced by electron donating substituents. Similar trends for donor ability were 
predicted through pKa values and calculated MEP values which matched perfectly with 
supramolecular yields showing the following trend for increasing donor ability, NH2 < CH3 < H < 
Cl < CN. (Figure 2.17) 
 
MEP/kJmol-1 124 140 144 163 185 
pKa 14.43 10.97 10.27 9.70 7.47 
Supramolecular yield 30% 55% 70% 80% 100% 
 
Figure 2.17 oximes arranged according to increasing donor ability with matching trends in 
MEP and pKA values. 
Based on the results obtained from solvent drop grinding experiments, the supramolecular 
yield can be tuned by changing the MEP value on the oxime moiety through covalent modification. 
The hydrogen bond donating ability of the oxime can be decreased by using electron donating 
groups as substituents and increased by using electron withdrawing substituents. 
 
Symmetric ditopic donors such as aliphatic di-carboxylic acids have been used to improve the 
physical properties of pharmaceuticals and agrochemicals by forming one dimensional chain type 
co-crystals24 (Figure 2.18).  
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Figure 2.18 Tuning the melting point of a pharmaceutical via co-crystallization24 
Exploring the same possibility with aromatic symmetric ditopic acids like terephthalic acid 
has been limited due to its lower solubility. The lower pKa of carboxylic acids (benzoic acid, pKa= 
4.2) results in the formation of salts with stronger bases25 which makes targeted supramolecular 
synthesis increasingly difficult26. Tuning the hydrogen bonding ability of acids is limited to 
functionalizing the aromatic rings in aromatic acids27. Symmetric ditopic oximes have better 
solubility compared to similar acids. They have pKa values that are much higher than that of 
carboxylic acids (Table 2.6) and therefore have a reduced tendency to form salts.  
Table 2.6 Calculated pKa values of the donors 
Donor 
di(NH2)ox di(CH3)ox di(H)ox di(Cl)ox di(CN)ox 
Terephthalic 
acid 
pKa23 14.43 10.97 10.27 9.70 7.47 3.51 
MEP/kJmol-1 124 140 144 163 185 154 
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Chapter 3. pKa vs calculated molecular electrostatic potential 
values: which is better at predicting molecular recognition? 
3.1. Introduction 
The synthesis of solid forms that consist of more than a single component (co-crystals) 
offer the possibility for a molecule of interest to exist in a variety of physical forms. Co-crystals 
provide means for modulating and fine-tuning physical properties such as melting point1, 
solubility,28 and hygroscopicity2 of a given compound without affecting its intrinsic chemical 
properties or activity. This function of multi-component solid-state architectures have drawn 
interest from areas such as pharmaceuticals28,3, agrochemicals4, non-linear optics5, explosives6, 
and organic semiconductors7. A clear understanding of the underlying non-covalent interactions 
and selectivity is required for the rational design of co-crystals. A comprehensive analysis of the 
Cambridge Structural Database for groups of neutral molecules with sterically accessible 
hydrogen- bonding groups was carried out by Etter and co-workers to determine the possible 
preferences for individual functional groups in terms of selectivity and patterns of aggregation in 
solids. Based on their results, a set of guidelines was proposed8. 
 All good proton donors and acceptors are used in hydrogen bonding 
 If a six-membered intramolecular hydrogen bond can form, it will usually do so in 
preference to forming intermolecular hydrogen bonds 
 The best proton donors and acceptors remaining after intramolecular hydrogen-bond 
formation, form intermolecular hydrogen bonds to one another 
To expand on rule number three we propose that in a competitive situation with multiple 
donors and acceptors, the best donor will selectively bind to the best acceptor and the second best 
donor will bind to the second best acceptor (Figure 3.1). 
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The classification of best donors and acceptors requires a way to rank hydrogen- bond 
donors and acceptors within some form of hierarchy.  
The direct use of pKa or pKa based methods have proven effective in some studies as 
predictors for hydrogen- bond donor ability. As shown in Figure 3.2, a ternary co- crystal was 
designed with the asymmetric ditopic acceptor iso-nicotinamide and two aromatic acids, where 
3,5-dinitrobenzoic acid (pKa 2.8) selectively binds to the pyridyl nitrogen, which is the stronger 
acceptor of iso-nicotinamide and 3-methylbenzoic acid (pKa = 4.3) binds to the weaker amide 
group.  
 
Figure 3.2 A 1:1:1 ternary cocrystal of  3,5-dinitrobenzoic acid : iso-nicotinamide : 3-
methylbenzoic acid designed based on pKa9 differences. 
A pKa based “slide rule”10 was proposed by Gilli et. al. using the concept of resonance 
assisted hydrogen bonding11. According to this approach, weaker hydrogen bonds are considered 
to be electrostatic and stronger hydrogen bonds have a covalent component that increases as the 
difference in pKa between the donor and the protonated acceptor approaches zero. The scale 
(Figure 3.3) consists of two columns of donors and protonated acceptors arranged according to 
pKa values and strongest donor acceptor pairs are matched along horizontal lines. The hierarchy 
of donors however, is still decided by the pKa values. 
Best acceptor 
Best donor 
Figure 3.1 The four possible outcomes with a pair of symmetric ditopic donors 
and acceptors (an expansion of Etter's rules). 
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Figure 3.3 The pKa slide scale10 
 
 The pKa based method appears to work well in systems limited to one type of donor 
functionality but does not hold well when comparing different donor groups. For example if we 
consider phenols and thiophenols, thiophenols (pKa = 6.61) have a higher pKa compared to 
phenols (pKa = 9.86) and are better donors according to the slide scale. Upon looking at 
experimental data, however phenols have proven to be strong hydrogen bond donors while 
thiophenols show little hydrogen bond donor ability compared to the12,13,14. 
A linear relationship was observed by Abraham et. al. when association constants (log K) 
for various acids were recorded for a given base (Figure 3.4).  Data analyzed similarly for 45 
different bases resulted in 45 linear relationships all in the form of Equation 3.115.  
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Figure 3.4 Plots of logK (acids against reference base) vs 𝒍𝒐𝒈𝑲𝑨
𝑯𝒊 15 
The 𝑙𝑜𝑔𝐾𝐴
𝐻𝑖 value characterizes the acid and the LB and DB values characterize the base. 
The 𝑙𝑜𝑔𝐾𝐴
𝐻𝑖 values can be used as a quantitative scale of hydrogen-bond acidity which can be 
calculated from experimentally obtained association constants16 using equation 3.1 
 
log 𝐾𝑖 =  𝐿𝐵𝑙𝑜𝑔𝐾𝐴
𝐻𝑖 + 𝐷𝐵    3.1 
 
The Abraham model for determining solute properties (SP) incorporates parameters to indicate 
hydrogen bonding ability as shown in equation 3.2 
log SP = c + eE + sS + aA + bB + vV   3.2 
 
E is the excess molar refraction, V is the McGowan volume, S is the 
dipolarity/polarizability, A is hydrogen bond acidity and B is hydrogen bond basicity. These values 
can be calculated from GLC or HPLC data17 by calibrating the stationary phase with solutes where 
the other values are known using Equation 3.2. Computational methods have also been used to 
predict Abraham parameters18,19.  
 
An alternative computational method was suggested by Hunter et. al.. who attempt to 
explain hydrogen bonding based on electrostatics. Where the association constant (K) of two 
simple molecules can be treated as  shown in Equation 3.3 where, αH2 and βH2  are functional group 
constants that relate to the hydrogen bond donor and hydrogen-bond acceptor properties. This is 
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equivalent to the expression of the electrostatics of the hydrogen bonding interaction, where the 
free energy of interaction changes with the product of the positive charge on the hydrogen-bond 
donor (αH2) and the negative charge on the hydrogen bond acceptor (βH2) 
 
log K = c1 αH2 βH2  + c2    3.3 
 
The charge parameter can be determined by a molecular electrostatic potential surface 
constructed around the molecule where the maxima correspond to the charges on the donors and 
the minima correspond to the charge on the acceptors (equation 3.4 and 3.5)20. 
 
α = Emax/52 kJmol-1 = 4.1 (αH2 + 0.33)   3.4 
β = -Emin/52 kJmol-1 = 10.3 (βH2 + 0.06)  3.5 
 
These α and β values can be used for the comparison and ranking of hydrogen bond donor 
and acceptor groups respectively 
 
An extension of the above approach was used to predict co-crystallization in systems with 
multiple donor and acceptor sites21. 
 
𝐸 =  − ∑ 𝛼𝑖𝛽𝑗𝑖𝑗      3.6 
Here α and β were calculated based on MEP values obtained using a higher level of theory where 
energy was minimized using DFT B3LYP/6-31+G* ab initio calculations. α and β values were  
calculated using equations 3.7 and 3.8. Calculated in this method were closer to experimental 
values compared to that by AM1. 
α = 0.0000162 MEPmax2  + 0.00962 MEPmax   3.7 
β = 0.000146 MEPmin2 - 0.00930 MEPmin   3.8 
 
In this chapter we will explore the possibility of using calculated molecular electrostatic 
potential values to qualitatively rank different hydrogen bond donor groups by screening 
asymmetric ditopic donors with geometrically unbiased acceptors.  
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For this study we have selected carboxylic acids, which according to its pKa is one of the 
strongest donor functionalities available (benzoic acid -  pKa = 4.20), to compare with phenols and 
aldoximes. Phenols are widely used as donor functionalities in the synthesis of co-crystals22, but 
are considered weaker donors due to their lower pKa values (phenol - pKa= 9.86). Similarly, 
aldoximes have shown potential as a hydrogen- bond donor functionality that is capable of forming 
co-crystals23, but it too has been considered to be weaker compared to carboxylic acids based on 
pKa. (benzaldehyde oxime - pKa=10.80)  No data has been published to date comparing these two 
functionalities. 
To examine the balance and competition between carboxylic acids phenols and aldoximes, 
we have selected three asymmetric ditopic donors, which contain the carboxylic acid functionality 
and with a phenol or an aldoxime group as shown in Figure 3.5.  These three donors were screened 
against nine geometrically unbiased acceptors shown in Figure 3.6. The selectivity of donors and 
acceptors can be established by studying the crystal structures obtained through single crystal X-
ray diffraction. 
 
Figure 3.5 asymmetric ditopic donors containing –COOH groups 
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Figure 3.6 The library of asymmetric ditopic acceptors 
 
The goals for this chapter are to, 
 Synthesize the required donors and acceptors from Figure 3.5 and Figure 3.6. 
 Perform DFT and AM1 molecular electrostatic potential calculations on the three donors 
and the nine acceptors. 
 Screen the donors against the acceptors using solvent assisted grinding and slow 
evaporation. 
 Examine structural data and evaluate the initial hypothesis.  
 
3.2. Experimental 
3.2.1. Synthesis 
All chemicals were purchased from Aldrich, Fisher Scientific and used without further 
purification, Melting points were determined on a GallenKamp melting point apparatus and are 
reported uncorrected. 1H and 13C NMR spectra were recorded on a Varian Unity plus 400 MHz 
spectrometer in DMSO-d6. Compounds were prepared for infrared spectroscopic (IR) analysis on 
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a ZnSe ATR crystal. 3-Hydroxybenzoic acid (3HBA) and 4-hydroxybenzoic acid (4HBA) were 
purchased from Sigma-Aldrich and used without further purification. 
1.1.1.1. Synthesis of 4-((hydroxyimino)methyl)benzoic acid, 4ABA 
 
4-Formylbenzoic acid (2.00 g, 13.3 mmol) and NH2OH.HCl (1.11 g 16.0 mmol) were 
ground together to a fine powder with a mortar and pestle. NaOH pellets (0.64 g, 16.0 mmol) were 
crushed and ground into the above mixture. Four drops of methanol were added and grinding was 
continued for two more minutes. The mixture allowed to stand for ten minutes, then ground again 
for two minutes. The absence of starting material was confirmed via TLC. The solid was dissolved 
in 200 ml of a 1:1 mixture of water and ethanol. Ethanol was removed under reduced pressure and 
the product was extracted into ethyl acetate, washed with brine and dried over MgSO4. The ethyl 
acetate was removed under reduced pressure to isolate an off white solid. (1.76 g 80%) m.p. 212 -
216 0C (lit. 218 0C)  1H NMR (400 MHz, DMSO-d6)  ppm 7.70 (2 H, d, J=8.59 Hz), 7.95 (8 H, 
d, J=8.20 Hz), 8.21 (1 H, s), 11.53 (1 H, s), 13.04 (1 H, br. s.) 
1.1.1.2. Synthesis of 1-(pyridin-4-ylmethyl)-1H-benzo[d]imidazole,  
 Benzimidazole (0.5 g, 4.23 mmol) was dissolved in 50 ml of acetonitrile. Crushed 
NaOH (0.508 g 12.7 mmol) was added to the solution and was stirred for 3 hours. 4-Picolylchloride 
hydrogen chloride (0.69 g, 4.23 mmol) was dissolved in 50 ml of acetonitrile and added to the 
benzimidazole solution and stirred for 6 hours. Once the absence of the picolyl chloride was 
confirmed via TLC, the acetonitrile was removed under reduced pressure. The resulting oil was 
dissolved in ethyl acetate and washed with 1 N NaOH, disilled water and brine. The solution was 
dried over MgSO4. Ethyl acetate was removed under reduced pressure to yield a brown solid. (5.40 
g, 69.4%) m.p. 105-110 °C (lit. 130 0C)24 1H NMR (DMSO-d6 ,400MHz): d = 8.51 (d, J=6.2 Hz, 
1 H), 8.42 (s, 1 H), 7.68 (dd, J=9.0, 3.5 Hz, 1 H), 7.46 (dd, J=9.4, 3.5 Hz, 1 H), 7.21 (dd, J=9.0, 
3.5 Hz, 1 H), 7.18 (d, J=5.5 Hz, 1 H), 5.58 ppm (s, 1 H) 
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3.2.2. Synthesis of co-crystals 
3.2.2.1. Synthesis of 4-hydroxybenzoic acid, 3PB (1:1), 4HBA:3PB 
4HBA (0.010g, 0.072 mmol) and  3PB (0.015 g, 0.072 mmol) were dissolved in 5 ml of 
ethanol with heat and allowed to stand at room temperature for slow evaporation. Colorless plates 
were obtained in two weeks. (m.p. 140 -1450C) 
3.2.2.2. Synthesis of 3-hydroxybenzoic acid, 3PB (1:1), 3HBA:3PB 
3HBA (0.010g, 0.072 mmol) and  3PB (0.015 g, 0.072 mmol) were dissolved in 5 ml of 
ethanol with heat and allowed to stand at room temperature for slow evaporation. Colorless prisms 
were obtained in two weeks.( m.p. 130 – 1400C) 
3.2.2.3. Synthesis of 4-hydroxybenzoic acid, 4PMB (1:1), 4HBA:4PMB 
4HBA (0.010g, 0.072 mmol) and 4PMB (0.017 g, 0.072 mmol) were dissolved in 5 ml of 
ethanol with heat and allowed to stand at room temperature for slow evaporation. Colorless plates 
were obtained in two weeks. (m.p. 110 – 120 0C) 
3.2.2.4. Synthesis of 3-hydroxybenzoic acid, 3PMB (1:1), 3HBA:3PMB 
3HBA (0.010g, 0.072 mmol) and  3PMB (0.017 g, 0.072 mmol) were dissolved in 5 ml of 
1:1 acetone:chloroform with a drop of methanol with heat and allowed to stand at room 
temperature for slow evaporation. Light brown blocks were obtained in five days. (m.p.70 -74 0C) 
3.2.2.5. Synthesis of 4-((hydroxyimino)methyl)benzoic acid, 1PB (1:1), 4ABA:1PB 
4ABA (0.010g, 0.061 mmol) and  1PB (0.013 g, 0.061 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Yellow prisms 
were obtained in two weeks. (m.p.88 - 90 0C) 
3.2.2.6. Synthesis of 4-((hydroxyimino)methyl)benzoic acid, 4PMB (1:1), 4ABA:4PMB 
4ABA (0.010g, 0.061 mmol) and  4PMB (0.013 g, 0.061 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
prisms were obtained in two weeks. (m.p. 131 - 135 0C) 
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3.3. Results 
3.3.1. Calculations 
3.3.1.1. Molecular electrostatic potential (MEP) calculations 
Table 3.1 MEP calculations on the donors show the carboxylic acid to be the weaker donor 
 AM1 MEP /kJmol-1 DFT MEP /kJmol-1 
 D1 D2 D1 D2 
 
191 138 305 244 
 
175 144 283 253 
 
154 139 276 258 
 
Based on the both DFT and AM1 MEP calculations the carboxylic acid is the weaker donor 
in all three donor molecules. The MEP based ranking of donor groups contradicts the pKa based 
ranking in all three cases. 
Table 3.2 MEP calculations for the acceptors 
Name 
AM1 MEP /kJmol-1 DFT MEP /kJmol-1 
A1 A2 A1 A2 
PzO -266 -232 -161 -144 
MPzO -287 -255 -177 -147 
BPO -294 -249 -182 -168 
4PI -291 -252 -200 -186 
1PB -290 -279 -182 -179 
3PB -292 -262 -201 -175 
4PB -291 -268 -195 -174 
3PMB -296 -261 -210 -180 
4PMB -291 -268 -203 -177 
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Similar to the donors the hierarchy of functional groups stays the same with the acceptors 
according to  AM1 and DFT calculations. 
3.3.2. Identification on co-crystals 
The formation of co-crystals was confirmed by IR spectroscopy based on the O-H∙∙∙N stretch 
(1800-1900 cm-1) and changes in the carbonyl peak, Fig 3.7 as an example. 
 
Figure 3.7 The IR spectrum of the crystal 4HBA:4PMB 
 
Table 3.3 Relevant IR results from solvent drop grinding experiments 
Acceptor 3-HBA 4-HBA 4-ABA 
 O-H∙∙∙∙∙N C==O O-H∙∙∙∙∙N C==O C==O O-H∙∙∙∙∙N C==N 
None - 1681 - 1669 1662 - 1609 
PzO - 1698 - 1691 1700 1832 1596 
MPzO 1932 1692 1904 1681 1683 - 1585 
BPO 1935 1687 1940 1666 1681 1884 1606 
4PI 1920 1665 1877 1686 1683 1904 1605 
1PB 1920 1685 1935 1680 1683 1866 1568 
3PB 1928 1693 1864 1666 1683 1925 1605 
4PB 1932 1693 1912 1671 1692 1921 1606 
3PMB 1935 1692 1912 1667 1688 1934 1582 
4PMB 1926 1694 1929 1667 1692 1933 1565 
6
9
7
.1
1
7
4
9
.8
6
7
6
3
.0
4
7
7
9
.7
2
7
9
8
.5
5
8
1
2
.1
8
8
4
3
.0
4
1
0
1
3
.7
5
1
0
6
7
.9
4
1
1
5
3
.6
3
1
2
2
3
.4
9
1
2
4
9
.1
8
1
5
0
2
.8
9
1
5
6
4
.9
2
1
5
8
7
.8
5
1
6
0
6
.5
11
6
4
5
.3
9
1
6
6
0
.2
7
1
6
7
2
.4
1
1
9
2
5
.3
7
2
3
2
2
.4
0
2
3
3
2
.4
1
2
3
4
3
.1
0
2
3
5
7
.7
2
 68
 70
 72
 74
 76
 78
 80
 82
 84
 86
 88
 90
 92
 94
 96
 98
 100
%
T
 1000   1500   2000   2500   3000   3500  
Wav enumbers  (cm-1)
49 
 
 
The OH∙∙∙N stretch and the significant changes in the C=O and C=N stretches indicate the 
formation of co-crystals in all 27 cases.  
3.3.3. Description of crystal structures 
3.3.3.1. Crystal structure of 4-hydroxybenzoic acid, 3PB (1:1), 4HBA:3PB 
 
The crystal structure of 4HBA:3PB consists of one molecule of 4-HBA and one molecule 
of 3PB.  The best donor, the –OH moiety, forms a hydrogen bond to the benzimidazole site, 
(O34∙∙∙N13 2.7238(13) Å) leaving the second-best donor, the –COOH group, to form a hydrogen 
bond with the second-best acceptor, the pyridyl nitrogen atom, (O31∙∙∙N21 2.6627(13) Å).(Figure 
3.8). 
 
Figure 3.8 The primary hydrogen-bond interactions in the crystal structure of 4HBA:3PB 
3.3.3.2. Crystal structure of 3-hydroxybenzoic acid, 3PB (1:1), 3HBA:3PB 
The crystal structure of 3HBA:3PB consists of one molecule of 3-HBA and one molecule 
of 3PB  where the –OH moiety, forms a hydrogen bond to the benzimidazole site, (O33∙∙∙N13 
2.6778(16) Å) and the –COOH forms a hydrogen bond with the second-best acceptor, the pyridyl 
nitrogen atom, (O31∙∙∙N21 2.6266(17) Å) (Figure 3.9). 
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Figure 3.9 The primary hydrogen-bond interactions in the crystal structure of 3HBA:3PB 
 
3.3.3.3. Crystal structure of 4-hydroxybenzoic acid, 4PMB (1:1), 4HBA:4PMB 
The crystal structure of 4HBA:4PMB consists of one molecule of 4-HBA and one 
molecule of 4PMB and ¼ of a water molecule. In this hydrated co-crystal, the best donor –OH 
moiety, forms a hydrogen bond to the benzimidazole site, (O44∙∙∙N13 2.683(3) Å), and the second 
best donor –COOH forms a hydrogen bond with the pyridyl nitrogen atom, second-best acceptor 
(O41∙∙∙N31 2.659(3) Å) (Figure 3.10)  
 
Figure 3.10 The primary hydrogen-bond interactions in the crystal structure of 
4HBA:4PMB 
3.3.3.4. Crystal structure of 3-hydroxybenzoic acid, 3PMB (1:1), 
3HBA:3PMB:CH3CN.H2O  
The crystal structure of 4HBA:4PMB consists of one molecule of 4-HBA and one molecule of 
4PMB. In this solvated co-crystal, the best donor –OH moiety, forms a hydrogen bond to the 
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benzimidazole site, (O43∙∙∙N13 2.728(3) Å), and the second best donor –COOH forms a hydrogen 
bond with the pyridyl nitrogen atom, second-best acceptor (O41∙∙∙N31 2.669(3) Å) (Figure 3.11) 
 
Figure 3.11 The primary hydrogen-bond interactions in the crystal structure of 
3HBA:3PMB:CH3CN.H2O 
3.3.3.5. Crystal structure of 4-((hydroxyimino)methyl)benzoic acid, 4PMB (1:1), 
4ABA:4PMB 
The crystal structure of 4ABA:4PMB consists of one molecule of 4-ABA and one molecule 
of 1PB. In this co-crystal, the best donor, oxime moiety, forms a hydrogen bond to the 
benzimidazole site, (O48∙∙∙N13 2.777(15) Å), and the second best donor –COOH forms a hydrogen 
bond with the pyridyl nitrogen atom, second-best acceptor (O41∙∙∙N31 2.637(16) Å) (Figure 3.12) 
 
Figure 3.12 The primary hydrogen-bond interactions in the crystal structure of 
4ABA:4PMB 
 
3.3.3.6. Crystal structure of 4-((hydroxyimino)methyl)benzoic acid, 1PB (2:1), 
4ABA:1PB 
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The crystal structure of 4ABA:1PB consists of two molecules of 4-ABA and one molecule 
of 1PB. In this co-crystal, the best donor oxime moiety, forms a hydrogen bond to the 
benzimidazole site, (O48∙∙∙N13 2.671(2) Å), and the second best donor –COOH forms a hydrogen 
bond with the pyridyl nitrogen atom, second-best acceptor (O31∙∙∙N21 2.704(2) Å) In addition, it 
forms an acid-acid dimer (O41∙∙∙O42 2.578(2) Å) and an oxime-oxime interaction (O38∙∙∙O48 
2.797(2) Å) (Figure 3.13) 
 
Figure 3.13 The primary hydrogen-bond interactions in the crystal structure of 4ABA:1PB 
3.4. Discussion 
3.4.1. Evaluation of co-crystals  
Our expansion of Etter’s rules propose that in a system comprising multiple hydrogen bond 
donor and acceptor groups the best donor will selectively bind to the best acceptor and the second 
best donor will bind to the second best acceptor and so on. In all six structures obtained, the best 
donor follows the same trend as the example shown in Figure 3.14 where the best donor as 
determined by MEP calculations selectively forms hydrogen bonds to the best acceptor. The 
carboxylic acid group, which according to the pKa based approaches, is the best donor by a few 
orders of magnitude acted as the weaker donor by picking up the weaker acceptor in all six cases. 
The water molecule in 4HBA:4PB does not break any of the anticipated O-HN interactions 
which are quite unusual in hydrates.25 
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3.4.2. Predicting molecular recognition based on pKa and MEP values 
The selectivity exhibited by the donors and acceptors in this study is in accordance with 
the predictions made based on the MEP calculations and completely contradicts predictions made 
using pKa as a ranking system.  This is because hydrogen bonding can be considered mostly 
electrostatic and pKa values indicate the potential for protonation or deprotonation rather than 
hydrogen bonding this value is affected by the electrostatic environment but is not a measure of 
hydrogen bond donor ability.  
A published co-crystal 4-hydroxybenzoic acid with 4PI which consists of pyridine and 
imidazole acceptor sites also shows that the weaker donor (the hydroxyl group), with the higher 
pKa group forms a hydrogen bond with the best acceptor site with the higher pKa value (Figure 
3.14). 
 
Figure 3.14 4-Hydroxybenzoic acid with an asymmetric ditopic acceptor26 
 
In addition unpublished data from our group for co-crystals of 4HBA:PzO (Figure 3.15) 
and 4HBA:BPO (Figure 3.16) also shows the same trend where in both cases the OH group picks 
up the N-oxide group which is the best acceptor in both cases and the second best donor, carboxylic 
acid picks up the pyridine and pyrazine nitrogen atoms, respectively.  
 
Figure 3.15 The primary hydrogen-bond interactions in the crystal structure of 4HBA:PzO 
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Figure 3.16 The primary hydrogen-bond interactions in the crystal structure of 4HBA:BPO 
Including this published structure and the unpublished data we observe that in nine 
instances where two donors of significantly different pKa value have provided co-crystals with 
geometrically unbiased acceptors, the outcome differs from that predicted by pKa values or pKa 
based approaches.  
A similar selectivity can be observed in the case of 4-hydroxybenzoic acid and the 
monotopic acceptor,4-phenylpyridine where pKa values suggest that the acid group is the best 
donor with a pKa almost five orders of magnitude higher than the hydroxyl group. But as shown 
in Figure 3.17, 4-phenylpyridine selectively binds to the hydroxyl group which is considered the 
weaker donor.  
 
Figure 3.17 The –OH group (the weaker donor according to pKa) forms a hydrogen bond 
with the pyridine instead of the acid. 
 
 
According to pKa values hydroxyl group is five orders of magnitude weaker than the 
carboxylic acid group and the aldehyde is almost seven orders of magnitude weaker. 
Experimentally we have observed that, both the oxime and the phenol pick out the stronger 
acceptor over the acid and therefore are stronger donors compared to the carboxylic acid. 
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Therefore, it seems that pKa may not be effective when comparing the hydrogen bond donor ability 
of different functional groups. The MEP based approaches (both DFT and AM1) on the other hand, 
have successfully predicted the outcomes of all seven co crystals. 
 
3.4.3. Conclusions 
Out of the existing method to predict supramolecular outcomes it was observed that pKa 
based prediction methods cannot be used in situations comparing different families of functional 
groups. The supramolecular outcomes of the nine co-crystals were correctly predicted by the 
calculated molecular electrostatic potential values where molecular recognition takes place based 
on our expansion of Etter’s rules.  
 
 
Figure 3.18 All nine co-crystals formed according to Etter's rules as predicted based on 
MEP values. 
Based on the experimental observations the phenol group and the aldoximes, both act as stronger 
hydrogen bond donors than carboxylic acids when the groups are on the same aromatic backbone. 
 
 
Best acceptor 
according to MEP 
 
Best donor according to MEP 
The best donor selectively binds to best acceptor 
according based on MEP calculations. 
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Chapter 4. Establishing the place of cyanooximes in the 
hierarchy of hydrogen-bond donors  
4.1. Introduction 
4.1.1. Cyanooximes 
The cyanooxime functionality can be found in fungicides1, pesticides2, organometallics3 
and the treatment of cancer4. Another unique attribute observed was that unlike all other oximes 
cyanooximes do not form an oxime-oxime dimer (Figure 4.1).  
 
Figure 4.1 (a)Typical oxime-oxime dimer  (b) Chain motif formed by cyanooximes5 
Our study of oximes in chapter two showed that based on supramolecular yield, 
cyanooximes proved to have the strongest donor ability of all the oximes studied (Figure 4.2). This 
was attributed to the electron withdrawing effect of the –CN group 
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MEP/kJmol-1 124 140 144 163 185 
pKa 14.43 10.97 10.27 9.70 7.47 
Supramolecular yield 30% 55% 70% 80% 100% 
 
Figure 4.2 Oximes arranged according to increasing donor based on observed 
supramolecular yields ability with matching trends in MEP and pKA values. 
4.1.2. Towards a unified theory for predicting selectivity in hydrogen-bonding 
The ability to predict molecular recognition events or supramolecular selectivity enables 
the rational deliberate design and synthesis of co-crystals. In the case of a molecule containing 
both donor and acceptor sites, a proper understanding of hydrogen-bond donor and acceptor 
hierarchy makes it possible to select potential co-crystalizing agents with donor and acceptor sites 
stronger than those on the molecule itself, thereby increasing the chance of forming co-crystals. 
This eliminates the need for extensive and expensive co-crystal screens.     
In chapter 3 it was shown that calculated molecular electrostatic potential values can be 
employed to predict hydrogen-bonding preferences between phenols carboxylic acids and 
aldoximes. These predictions were verified by experimental results. A unified theory to predict 
molecular recognition should be applicable to any system. In this chapter we attempt to predict the 
hydrogen-bond donating ability of cyanooximes compared to phenols and carboxylic acids based 
on molecular electrostatic potential values. 
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4.1.3. Virtual co-crystal screening 
A method has been developed by Hunter et. al6., to predict the possibility of co-crystal 
formation by calculating the difference in energy between, the overall paring energies (eqn. 4.1)  
of the individual components and the co-crystal. 
𝐸 = − ∑ 𝛼𝑖𝛽𝑗𝑖𝑗   4.1   
α (eqn. 4.2) and β (eqn. 4.3)  are based on MEP values obtained using a higher level of theory 
where the molecular geometry was minimized using DFT B3LYP/6-31+G* ab initio calculations. 
α and β values were  calculated using equations 4.2 and 4.3. This level of theory provided a better 
fit compared to AM1. 
α = 0.0000162 MEPmax2  + 0.00962 MEPmax  4.2 
β = 0.000146 MEPmin2 - 0.00930 MEPmin  4.3 
 
By running this analysis on around 846 compounds on the EAFUS list (Everything added 
to food in the United States) it was observed that 80% of the experimental hits were in the top 11% 
of the ranking based on analysis. Based on their observations they have set a cut-off value of 11 
kJ/mol between the individual constituents and the co-crystal would give a 50% chance of co-
crystal formation. 
In this study, in addition to ranking based on calculated MEP values, we will attempt to 
use the same method to calculate the difference in energy between the predicted binding interaction 
(D1…A1 and D2…A2) and alternative combinations of donors and acceptors (D1…A2 and D1…A2) 
in order to see if energy calculations for different expected outcomes can be used to predict the 
actual supramolecular outcome. 
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4.1.4. Hypothesis 
 
Figure 4.3 Hypothesis on selectivity based on Etter's rules7,8 (Figure 4.3) 
 
Based on our extension of Etters rules7,8, when combining asymmetric ditopic donors and 
acceptors the best donor should selectively bind to the best acceptor and the second best donor 
should bind the second best acceptor if our method of ranking donors and acceptors still holds 
when comparing the cyanooxime group with the phenol and carboxylic acid groups.  
 
The goals of the work described in this chapter are, 
 To synthesize three asymmetric ditopic donors containing cyanooxime groups  
 
Figure 4.4 Three asymmetric ditopic donors with a cyanooxime functionality. 
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 Perform DFT and AM1 molecular electrostatic potential calculations on the three donors 
and the nine acceptors. 
 
Figure 4.5 The nine acceptors used in this study 
 
 Calculate relative energies of donor acceptor pairs for possible outcomes. 
 Screen the three donors (Figure 4.4) against the nine (Figure 4.5) acceptors using solvent 
assisted grinding and slow evaporation. 
 Examine structural data and evaluate the initial hypothesis.  
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4.2. Experimental 
4.2.1. Molecular electrostatic potential calculations 
 
Table 4.1  AM1 and DFT molecular electrostatic potential surface on the three donors. 
Donor 
AM1 DFT 
D1 D2 D1 D2 
 
181 171 302 290 
 
192 147 314 269 
 
183 147 298 282 
 
As shown in Table 4.1, both DFT and AM1 calculations show the same donor hierarchy in 
all three ditopic donor molecules. Based on the calculated MEP values of 4-hydroxycyanooxime 
the phenol is a better donor compared to the cyanooxime. With 3 and 4-acidcyanooximes however, 
the cyanooxime proves to be the better donor compared to the carboxylic acid based on the 
calculated MEP values. 
 
Table 4.2 Calculated AM1 and DFT molecular electrostatic potential values of the acceptors 
Name 
AM1 MEP /kJmol-1 DFT MEP /kJmol-1 
A1 A2 A1 A2 
PzO -266 -232 -161 -144 
MPzO -287 -255 -177 -147 
BPO -294 -249 -182 -168 
3PI -290 -279 -204 -171 
1PB -290 -279 -182 -179 
3PB -292 -262 -201 -175 
63 
 
4PB -291 -268 -195 -174 
3PMB -296 -261 -210 -180 
4PMB -291 -268 -203 -177 
 
4.2.2. Synthesis of asymmetric ditopic donors 
All chemicals were purchased from Aldrich, Fisher Scientific and used without further 
purification, Melting points were determined on a GallenKamp melting point apparatus and are 
reported uncorrected. 1H and 13C NMR spectra were recorded on a Varian Unity plus 400 MHz 
spectrometer in DMSO-d6. Compounds were prepared for infrared spectroscopic (IR) analysis on 
a ZnSe ATR crystal. 
4.2.2.1. Synthesis of (Z)-N,4-dihydroxybenzimidoyl cyanide, PhOx  
 
10 g of NaOH was dissolved in 250 ml of methanol. 2.0 g (15.0 mmol) of 2-(4-
hydroxyphenyl)acetonitrile was dissolved in 50 ml of methanol and added to the NaOH solution 
and allowed to stir for 1 hour. Methyl nitrite was bubbled through the solution over 30 minutes. 
The resulting solution was allowed to stir at room temperature for 48 hours. 
Methanol was removed under reduced pressure. The solid was dissolved in 100 ml of water 
and cooled in an ice bath. The pH was then slowly lowered to pH=2 with 6 M HCl. The precipitate 
was filtered and washed with ice water. 1.58 g of pure product was obtained. (Yield 65%) M.p.: 
160-165 oC 1H NMR (400 MHz, DMSO-d6)  ppm 6.89 (d, J=8.59 Hz, 2 H) 7.55 (d, J=8.98 Hz, 
2 H) 10.13 (br. s., 1 H) 13.29 (br. s., 1 H) 
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4.2.2.2. (Z)-4-(cyano(hydroxyimino)methyl)benzoic acid, 4BaOx 
 
Figure 4.6 Synthetic scheme for 4BaOx 
4.2.2.2.1. Synthesis of 4-(bromomethyl)benzoic acid 
5 g (36 mmol) of 4-toluic acid was added to 100 ml ethyl acetate. To the resulting slurry a 
solution of 10 g (66 mmol) sodium bromate in 50 ml of water was added. 7 g (66 mmol) of NaHSO3 
was dissolved in 44 ml of water and added dropwise to the 4-toluic acid solution via a dropping 
funnel over a time of 20 minutes. The resulting solution was stirred overnight at room temperature. 
The ethyl acetate was removed under reduced pressure. The resulting white solid was filtered and 
washed with water. m.p. 200 – 205 0C (lit 228-232 0C)9 (6.3 g, 82%) 1H NMR (200 MHz, DMSO-
d6)  ppm 4.76 (2 H, s), 7.56 (2 H, d, J=8.35 Hz), 7.92 (2 H, d, J=8.35 Hz), 13.10 (1 H, br. s.) 
4.2.2.2.2. Synthesis of 4-(cyanomethyl)benzoic acid 
2.6 g (12.2 mmol) of 4-(bromomethyl)benzoic acid was dissolved in 100 ml of ethanol and 
50 ml water. 1.02g (12.2 mmol) NaHCO3 was added to the stirring solution with 1.19 g (24.4 
mmol) of sodium cyanide. The solution was stirred at room temperature for 6 hours. 
Ethanol was removed under reduced pressure. 50 ml of water was added to the resulting 
slurry and acidified in an icebath with 2 M HCl. The solid obtained was filtered and washed with 
water to yield a light brown solid m.p. 193 – 198 0C (lit 195-200 0C)10 (1.9 g, 96%) 1H NMR (200 
MHz, DMSO-d6)  ppm 4.15 (2 H, s), 7.47 (2 H, d, J=8.06 Hz), 7.95 (2 H, d, J=8.42 Hz) 
4.2.2.2.3. (Z)-4-(cyano(hydroxyimino)methyl)benzoic acid, 4BaOx  
10 g of NaOH was dissolved in 250 ml of methanol. 1.9 g (11.8 mmol) of 4-
(cyanomethyl)benzoic acid was dissolved in 50 ml of methanol and added to the NaOH solution 
and allowed to stir for 1 hour. Methyl nitrite was generated by pouring a solution of 16 ml H2SO4 
in 32 ml of water dropwise into a solution of NaNO2 in 100 ml water and 50 ml methanol. Methyl 
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nitrite was bubbled through the solution over 30 minutes. The resulting solution was allowed to 
stir at room temperature for 48 hours. 
The color of the solution changed from yellow to orange. Methanol was removed with 
reduced pressure. The solid was dissolved in 100 ml of water and cooled in an ice bath. The pH 
was then slowly lowered to pH=2 with 6 M HCl. The off white solid obtained was filtered and 
washed with ice water. (1.34 g Yield 60%) M.p. 255-260 oC 1H NMR (200 MHz, DMSO-d6)  
ppm 7.83 (2 H, d, J=1.00 Hz), 8.05 (2 H, d, J=1.00 Hz), 13.25 (1 H, br. s), 14.09 (1 H, br. s.) 
4.2.2.3. (Z)-3-(cyano(hydroxyimino)methyl)benzoic acid, 3BaOx  
 
Figure 4.7 Synthetic scheme for 3BaOx 
4.2.2.3.1. Synthesis of 3-(bromomethyl)benzoic acid, 
5 g (36 mmol) of 4-toluic acid was added to 100 ml ethyl acetate. To the resulting slurry a 
solution of 10 g (66 mmol) sodium bromate in 50 ml of water was added. 7 g (66 mmol) of NaHSO3 
was dissolved in 44 ml of water and added dropwise to the 4-toluic acid solution via a dropping 
funnel over a time of 20 minutes. The resulting solution was stirred overnight at room temperature. 
The ethyl acetate was removed under reduced pressure. The resulting white solid was filtered and 
washed with water. (6.3 g, 75%) m.p. 153 – 157 0C (lit. 155 – 156 0C)11 1H NMR (200 MHz, 
DMSO-d6)  ppm 4.76 (2 H, s), 7.56 (2 H, d, J=8.35 Hz), 7.92 (2 H, d, J=8.35 Hz), 13.10 (1 H, br. 
s.) 
Synthesis of 3-(cyanomethyl)benzoic acid, 
2.6 g (12.2 mmol) of 4-(bromomethyl)benzoic acid was dissolved in 100 ml of ethanol and 
50 ml water. 1.02g (12.2 mmol) NaHCO3 was added to the stirring solution with 1.19 g (24.4 
mmol) of sodium cyanide. The solution was stirred at room temperature for 6 hours. 
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Ethanol was removed under reduced pressure. 50 ml of water was added to the resulting 
slurry and acidified in an icebath with 2 M HCl. The solid obtained was filtered and washed with 
water. 1.9 g of product was obtained. (Yield 85%) m.p 176 – 180 0C (lit. 175 – 176 0C)12 
(Z)-3-(cyano(hydroxyimino)methyl)benzoic acid, 3BaOx  
10 g of NaOH was dissolved in 250 ml of methanol. 1.9 g (11.8 mmol) of 3-
(cyanomethyl)benzoic acid was dissolved in 50 ml of methanol and added to the NaOH solution 
and allowed to stir for 1 hour. Methyl nitrite was was generated by pouring a solution of 16 ml 
H2SO4 in 32 ml of water dropwise in to a solution of 10 g NaNO2 in 100 ml water and 50 ml 
methanol.. Methyl nitrite was bubbled through the solution over 30 minutes. The resulting solution 
was allowed to stir at room temperature for 48 hours. 
The color of the solution changed from yellow to orange. Methanol was removed with 
reduced pressure. The solid was dissolved in 100 ml of water and cooled in an ice bath. The pH is 
then slowly lowered to pH=2 with 6 M HCl. The solid obtained was filtered and washed with ice 
water. 1.34 g of product was obtained. (Yield 60%) M.p.: 230-233 oC dec.  1H NMR (DMSO-d6 
,200MHz):  = 13.99 (br. s., 1 H), 13.39 (br. s., 1 H), 8.07 (d, J=7.8 Hz, 1 H), 7.97 (d, J=1.0 Hz, 
1 H), 7.66 ppm (s, 1 H) 
4.2.3. Synthesis of co-crystals 
4.2.3.1. Synthesis of  PhOx:MPzO (1:1) 
PhOx (0.010g, 0.062 mmol) and MPzO (0.009 g, 0.062 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
prisms were obtained in a week. (m.p.160 – 165 0C) 
4.2.3.2. Synthesis of 4-hydroxycyanooxime, BPO (1:1) PhOx:BPO 
PhOx (0.010g, 0.062 mmol) and BPO (0.011 g, 0.062 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
prisms were obtained in three weeks. (m.p.163 – 168 0C). 
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4.2.3.3. Synthesis of 4-hydroxycyanooxime, 4PI (1:1) PhOx:4PI 
PhOx (0.010g, 0.062 mmol) and 4PI (0.015 g, 0.062 mmol) were dissolved in 5 ml of methanol 
with heat and allowed to stand at room temperature for slow evaporation. Colorless prisms were 
obtained in two weeks. (m.p.150 – 154 0C) 
4.2.3.4. Synthesis of 4-hydroxycyanooxime, 3PMB (1:1) PhOx: 3PMB 
PhOx (0.010g, 0.062 mmol) and 3PMB (0.015 g, 0.062 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
plates were obtained in ten days. (m.p.175 – 178 0C) 
4.2.3.5. Synthesis of 4-hydroxycyanooxime, 4PMB (1:1) PhOx: 4PMB 
PhOx (0.010g, 0.062 mmol) and 4PMB (0.015 g, 0.062 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
prisms were obtained in two weeks. (m.p.135 – 141 0C) 
4.2.3.6. Synthesis of 4-acidcyanooxime, PzO (1:1) 4BAOx:PzO  
4BAOx (0.010g, 0.053 mmol) and PzO (0.005 g, 0.053 mmol) were dissolved in 5 ml of 
ethanol with heat and allowed to stand at room temperature for slow evaporation. Colorless plates 
were obtained in two weeks. (m.p. 170 0C) 
4.2.3.7. Synthesis of 4-acidcyanooxime, MPzO (1:1) 4BAOx:MPzO  
4BAOx (0.010g, 0.053 mmol) and MPzO (0.008 g, 0.053 mmol) were dissolved in 5 ml 
of ethanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
plates were obtained in three weeks. (m.p. 200 - 2060C) 
4.2.3.8. Synthesis of 3-acidcyanooxime, 4PMB (1:1) 3BAOx:4PMB 
3BAOx (0.010g, 0.053 mmol) and 4PMB (0.012 g, 0.053 mmol) were dissolved in 5 ml 
of methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
plates were obtained in ten days. (m.p. 175 – 180 0C) 
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4.2.3.9. Synthesis of 3-acidcyanooxime, 4PB (1:1) 3BAOx:4PB 
3BAOx (0.010g, 0.053 mmol) and 4PB (0.012 g, 0.053 mmol) were dissolved in 5 ml of 
methanol with heat and allowed to stand at room temperature for slow evaporation. Colorless 
plates were obtained in a week. (m.p. 125 - 130 0C) 
4.3. Results 
4.3.1. Description of crystal structures 
4.3.1.1. Crystal structure of PhOx:MPzO 
 
Figure 4.8 The primary hydrogen-bond interactions in the crystal structure of PhOx:MPzO 
 
The crystal structure determination of PhOx:MPzO shows that in the resulting 1:1 co-
crystal the best donor, the –OH moiety, forms a hydrogen-bond to the N-oxide oxygen atom, the 
best acceptor, (O14∙∙∙O21 2.6631(15) Å, O14-H14∙∙∙O21 1.70(2) Å), and the second best donor 
cyanooxime engages in a hydrogen-bond with the pyridyl nitrogen atom, the second-best acceptor, 
(O17∙∙∙N24 2.7223(16) Å, O17-H17∙∙∙N24 1.69(2) Å) (Figure 4.8) 
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4.3.1.2. Crystal structure of PhOx:BPO 
 
 
Figure 4.9 The primary hydrogen-bond interactions in the crystal structure of PhOx:BPO 
 In the crystal structure of PhOx:BPO, a 1:1 co-crystal, the best donor, –OH moiety 
forms a hydrogen-bond to the N-oxide oxygen atom, the best acceptor, (O14∙∙∙O21 2.6052(19) Å, 
O14-H14∙∙∙O21 1.71(3) Å), and cyanooxime, the second- best donor, forms a hydrogen-bond with 
the second- best acceptor, the pyridyl nitrogen atom, (O17∙∙∙N31 2.665(2), O17-H17∙∙∙N31  1.64 
Å) (Figure 4.9) 
 
4.3.1.3. Crystal structure of PhOx:3PI 
 
Figure 4.10 The primary hydrogen-bond interactions in the crystal structure of PhOx:3PI 
The 1:1 co-crystal of PhOx:3PI shows that the best donor, the –OH moiety, of PhOx 
interacts with the best acceptor, the imidazole site, (O44∙∙∙N13 2.6695(15) Å, O44-H44∙∙∙N13 
1.685(18) Å), whereas the second- best donor, cyanooxime, forms an O-HN hydrogen-bond with 
the pyridyl nitrogen atom (O47∙∙∙N21 2.6539(14) Å, O47-H47∙∙∙N21  1.673(18) Å) (Figure 4.10) 
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4.3.1.4. Crystal structure of PhOx:3PMB 
 
 
Figure 4.11 The primary hydrogen-bond interactions in the crystal structure of 
PhOx:3PMB 
 The crystal structure determination of PhOx:3PMB shows that in the resulting 1:1 
co-crystal the phenol, the best donor prefers to bind to the best acceptor, the benzimidazole site, 
(O44∙∙∙N13 2.7405(14) Å, O44-H44∙∙∙N13 1.852(17) Å), while the second-best donor, cyanooxime 
binds the pyridyl nitrogen which is the second- best acceptor (O47∙∙∙N31 2.6474(14) Å, O47-
H47∙∙∙N31  1.693(18) Å) (Figure 4.11). 
4.3.1.5. Crystal structure of PhOx:4PMB 
 
 
Figure 4.12 The primary hydrogen-bond interactions in the crystal structure of 
PhOx:4PMB. 
 
The crystal structure determination of PhOx:4PMB produced the an unexpected result. 
First, the stoichiometry is unexpected with a 1:2 ratio of PhOx to 4PMB.  Second, both donor 
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sites form hydrogen-bonds to the better acceptor, the imidazole moiety, O74N43 2.6990(12) Å, 
O74-H74N43 1.759(17) Å and O77∙∙∙N13 2.7627(12) Å, O77-H77∙∙∙N13 2.7627(12) Å with D1 
and D2, respectively, Figure 4.12. 
4.3.1.6. Crystal structure of  3BAOx:4PB 
 
Figure 4.13 The primary hydrogen-bond interactions in the crystal structure of 
3BAOx:4PB. 
The crystal structure determination of 3BAOx:4PB shows that in the resulting 1:1 co-
crystal the cyanooxime, the best donor prefers to bind to the best acceptor, the benzimidazole site, 
(O37A∙∙∙N13A 2.6514(18) Å) the second best donor, the carboxylic acid picks up the pyridine, the 
second best acceptor. O39∙∙∙N21 2.5965(14) Å (Figure 4.13) 
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4.3.1.7. Crystal structure of 3BAOx:4PMB 
 
Figure 4.14 The primary hydrogen-bond interactions in the crystal structure of 
3BAOx:4MPB 
The crystal structure determination of 3BAOx:4MPB shows that in the resulting 1:1 co-
crystal the cyanooxime, the best donor prefers to bind to the best acceptor, the benzimidazole site, 
(O47A∙∙∙N13A 2.6641(14) Å) the second best donor, the carboxylic acid binds to the pyridine, the 
second best acceptor. O49∙∙∙N21 2.5823(13) Å (Figure 4.14) 
 
4.3.1.8. Crystal structure of 4BAOx:PzO 
 
Figure 4.15 The primary hydrogen-bond interactions in the crystal structure of 4BaOx:PzO 
  
The crystal structure determination of 4BAOx:PzO yields an unexpected result where the 
best donor, the cyanooxime forms a hydrogen-bond with the second best acceptor, pyrazine 
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nitrogen (O17∙∙∙N24  2.674(2) Å) and the second best donor, carboxylic acid picks up the best 
acceptor, N-oxide group. (O19∙∙∙N21 2.684(2) Å) forming a one dimensional chain.(Figure 4.15) 
4.3.1.9. Crystal structure of 4BAOx:MPzO 
 
Figure 4.16 The primary hydrogen-bond interactions in the crystal structure of 
4BaOx:MPzO 
 The asymmetric unit of 4BAOx:MPzO has many different interactions, the best donor, 
cyanooxime group forms a hydrogen bond to the N-oxide (O27A∙∙∙O34  2.533(2) Å), the second 
best acceptor, the pyrazine nitrogen atom also forms a hydrogen bond to a cyanooxime group 
(O17∙∙∙O31  2.746(2) Å). The second best donor, acid group forms a hydrogen bond to the pyrazine 
nitrogen atom. (O29∙∙∙N54  2.716(2) Å) an acid group also forms an acid-acid dimer (O19∙∙∙N20  
2.618(2) Å) (Figure 4.16) 
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4.3.2. Calculation of pairing energies for possible supramolecular outcomes 
Table 4.3 pairing energy calculations for 4-Phenolcyanooxime 
Acceptor 
Self pairing of 
the donor 
Self pairing of 
the acceptor 
Phenol win 
Cyanooxime 
win 
Difference between 
The two outcomes 
PzO 34.417 15.935 4.145 3.934 0.211 
MPzO 34.417 10.174 9.009 8.617 0.392 
BPO 34.417 21.827 10.291 10.096 0.195 
3PI 34.417 19.097 20.582 20.235 0.347 
1PB 34.417 19.813 13.181 13.138 0.043 
3PB 34.417 23.718 14.951 14.565 0.386 
4PB 34.417 23.343 13.794 13.488 0.306 
3PMB 34.417 24.592 17.705 17.246 0.459 
4PMB 34.417 23.942 15.937 15.548 0.389 
 
Table 4.4 pairing energy calculations for 4-acidcyanooxime 
Acceptor 
Self-pairing of 
the donor 
Self-pairing of 
the acceptor 
Cyanooxime 
win 
Acid win 
Difference between 
The two outcomes 
PzO 38.259 15.935 -0.591 -0.869 0.278 
MPzO 38.259 10.174 3.421 2.904 0.516 
BPO 38.259 21.827 5.392 5.135 0.257 
3PI 38.259 19.097 14.717 14.260 0.457 
1PB 38.259 19.813 7.812 7.755 0.057 
3PB 38.259 23.718 9.784 9.277 0.507 
4PB 38.259 23.343 8.443 8.040 0.403 
3PMB 38.259 24.592 12.370 11.766 0.604 
4PMB 38.259 23.942 10.444 9.932 0.512 
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Table 4.5 pairing energy calculations for 3-Acidcyanooxime 
Acceptor 
Self pairing of 
the donor 
Self pairing of 
the acceptor 
Cyanooxime 
win 
Acid win 
Difference between 
The two outcomes 
PzO 37.904 15.935 4.145 3.934 0.211 
MPzO 37.904 10.174 9.009 8.617 0.392 
BPO 37.904 21.827 10.291 10.096 0.195 
3PI 37.904 19.097 20.582 20.235 0.347 
1PB 37.904 19.813 13.181 13.138 0.043 
3PB 37.904 23.718 14.951 14.565 0.386 
4PB 37.904 23.343 13.794 13.488 0.306 
3PMB 37.904 24.592 17.705 17.246 0.459 
4PMB 37.904 23.942 15.937 15.548 0.389 
 
In the case of all three donors large pairing energies observed suggest a high susceptibility 
for co-crystallization.  The energy difference between the predicted outcome and the alternative 
are less than 2 kJ/mol.  
4.4. Discussion 
A few optimizations were made to the reported synthetic methods13 in order to increase 
yields and reduce reaction time. For the conversion of the acetonitrile groups to cyanooximes, 
using a solution of NaOH in methanol instead of sodium in isopropanol did not have any adverse 
effect on the yield and it reduced the preparation time for the reaction as the tedious preparation 
of a sodium isopropoxide solution was not required.  p-toluic acid and m-toluic acid were used as 
starting material instead of their more expensive chloromethyl analogues.  
According to the MEP calculations the cyanooxime group is stronger than the carboxylic 
acid group and weaker than the phenol. All five structures obtained with 4-hydroxycyanooxime 
follow the preferences predicted by MEP calculations where, the best donor, phenol selectively 
hydrogen-bonded to the best acceptor and the cyanooxime which is the second best donor picked 
up the second best acceptor. Therefore the hierarchy between the phenol and cyanooxime was 
successfully predicted based on the calculated MEP values (table 4.6) 
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In the cases of 3 and 4-acidcyanooxime MEP calculations show the cyanooxime to be the 
better donor compared to the acid. Out of the four structures obtained, two exhibit the behavior 
predicted where the cyanooxime binds to the best acceptor and the acid group picks up the second 
best acceptor. Out of the remaining structures, in the asymmetric unit of 4-Acidcyanooxime:MPzO 
we observe two instances of  the cyanooxime binding to the N-oxide group which is the best 
acceptor, the acid picks up the pyrazine nitrogen in one case and forms a two point acid-acid dimer 
in the other. Even though the exact predicted interactions were not observed in this case the 
cyanooxime appears to dominate as the stronger donor picking up the best acceptor and the second 
best acceptor. In the case of 4-acid cyanooxime and PzO however, the cyanooxime group picks up 
the pyrazine nitrogen (D1•••A2) and the carboxylic acid binds to the N-oxide site (D2•••A1) which 
contradicts the predictions made based on MEP calculations (Table 4.6) 
Table 4.6 Outcomes for the nine co-crystals obtained 
Donor Acceptor D1•••A1 D1•••A2 D2•••A1 D2•••A2 
 
 
√ X X √ 
 
√ X X √ 
 
√ X X √ 
 
√ X X √ 
 
√ X X √ 
 
√ X X √ 
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√ X X √ 
 
 
√ √ X √ 
 
X √ √ X 
 
A survey of the Cambridge structure database on molecules containing the same 
combinations of donors yielded a the 1:1 binary co-crystal for 4BaOx:4PMB where the as 
predicted the best donor, cyanooxime group binds to the benzimidazole, the best acceptor and the 
acid group which is the second best donor picks up the pyridine. 
 
Figure 4.17 The published structure of the 1:1 co-crystal of 4BaOx and 4PMB14 
In total out of the ten asymmetric ditopic acceptors containing the cyanooxime 
functionality nine showed the supramolecular selectivity predicted by the ranking based on 
calculated MEP values. 
 The calculated pairing energies in many of the cases give values around and above 11 
kJ/mol predicting co-crystal formation. However the energy differences between the predicted 
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outcome and the possible alternative to be less than 2 kJ/mol . Therefore predictions on possible 
supramolecular outcomes cannot be made using this method. 
In this chapter we have shown that even in the case of weak and reversible supramolecular 
interactions nine out of ten times, the outcome was predicted using calculated MEP values with 
the cyanooxime group. This further proves that predicted MEP values can be used to predict the 
supramolecular outcomes over a variety of systems 
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Chapter 5. Exploring the structural landscape of 1-deazapurine 
5.1. Tautomerism 
Tautomerism is a form of isomerism where two versions of the same molecule are readily 
interconvertible1. For two isomers to be considered as tautomers, the free energy difference 
between the tautomers should be below 25 kcal/mol and both tautomers should be present in the 
system2. The migrating group X (Figure 5.1) can either be an electrofuge or a nucleofuge. Where 
the electrofuge is the proton, the resulting tautomerism is called prototropism or protontopic 
tautomerism. 
 
Figure 5.1 A pair of tautomers where the group X acts as either an electrofuge or a 
nucleofuge during isomerization1 
Prototropic tautomerism differs from other types of tautomerism. Due to the small size of protons, 
sterics have little effect on this type of tautomerism and since protons can engage in hydrogen 
bonding, the hydrogen bonding environment can have a significant effect on the rate and 
equilibrium. Tautomeric forms of a molecule differ in shape, functional groups3, and hydrogen-
bonding pattern 4(Figure 5.2) 
 
Figure 5.2 The five most stable tautomeric forms of cytosine3. 
The presence of multiple tautomers presents a challenge in covalent synthesis as shown in Figure 
5.3, as different tautomers can yield different constitutional isomers. 
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Figure 5.3 Each tautomer of 1-deazapurine leads to a different isomeric product5. 
5.2. Purines and deazapurines 
Purines are vital components of nucleic acids that are essential for all known forms of life. In 
addition purines are the main functionalities in some pharmaceuticals6 and organometallics7. This 
family of compounds also exhibit prototropic tautomerism. In the case of purines the two major 
tautomers (N(7)H and N(9)H) are observed8 that have very different hydrogen- bonding 
environments9(Figure 5.4).  
 
 
Figure 5.4 Different hydrogen bonding environments of adenine (left) and 1-deazapurine 
(right) 
Deazapurine exhibits the same type of tautomerism as adenine but has fewer donor and 
acceptor sites and better aqueous solubility compared to purines making them ideal model 
molecules for studying prototropism. In addition, 1-deazapurine (imidazo[4,5-b]pyridine) 
derivatives are used as algesics10 , antidepressants11,  antiviral agents12 and cytotoxins13. DFT 
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calculations show that in the gas phase there is a 11.15 kJ/mol energy difference between the two 
tautomers favoring the 3H tautomer but in the aqueous phase this difference falls below 1 kJ/mol. 
Both the 1H and 3H tautomers are observed in aqueous solutions14. 
5.3. Supramolecular control of tautomerism 
As equilibrium of prototropic tautomers can be affected by the local hydrogen bonding 
environment, it should in principle be possible to use supramolecular reagents to change the 
distribution of tautomers and even to isolate a desired tautomer in the solid state. In the case of 
deazapurine, the reported structure15 in the solid state shows the 1H tautomer forming a one 
dimensional chain formed by the N-H group on the imidazole ring picking up the aromatic nitrogen 
atom on the imidazole ring (Figure 5.5)  
 
Figure 5.5 The primary hydrogen-bonding interactions in the crystal structure of 1-
deazapurine 
In the case of the 3H, tautomer we would expect it to form a self-complementary dimer 
involving the imidazole N-H group and the pyridyl N atom. In order to facilitate the formation of 
this dimer we could introduce a strong hydrogen-bond donor which can pick up the imidazole 
nitrogen atom. 
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Figure 5.6 Possible synthons for stabilizing the possible supramolecular outcome for the 3H 
tautomer 
Table 5.1 shows the selected hydrogen and halogen bond donors that were used to stabilize 
and isolate the 3H tautomer, which we have separated in to three groups, symmetric ditopic 
hydrogen-bond donors which can form one dimensional chains incorporating the desired tautomer 
of 1-deazapurine(Figure 5.6 a). Monotopic hydrogen-bond donors that can stabilize the dimers as 
tetramers (Figure 5.6 b). Since 1-deazapurine has more than one acceptor site it is possible that 
strong hydrogen-bond donors could disrupt the dimer. Halogen bond donors might prove to be a 
suitable alternative (Figure 5.6 c). 
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Table 5.1 Selection of hydrogen and halogen bond donors 
Ditopic hydrogen-bond 
donors 
Monotopic hydrogen-bond 
donors 
Halogen bond donors 
  
 
  
 
  
 
   
 
  
 
 
The goals for this chapter are to: 
 Synthesize and characterize 1-deazapurine; 
 Perform DFT calculations on the donors and acceptors; 
 Attempt to isolate the 3H tautomer of 1-deazapurine by co-crystallizing with hydrogen 
and halogen bond donors; 
 Synthesize co-crystals of deazapurine with selected donors. 
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5.4. Experimental 
5.4.1. Synthesis 
 
Figure 5.7 Synthetic scheme for 1-deazapurine. 
 
5.4.1.1. Synthesis of 2-amino-5-bromopyridine 
 
2-Aminopyridine (5 g, 53 mmol) was dissolved in 150 ml of acetonitrile. 20 g of 
ammonium acetate was added to it. NBS (9.9g, 53 mmol) was slowly added to the stirring 
suspension dropwise. The absence of starting material was confirmed via TLC in about 15 minutes. 
The acetonitrile was removed under reduced pressure. The solid was dissolved in ethyl acetate, 
washed with water and brine and dried over MgSO4. Ethyl acetate was removed under reduced 
pressure yielding a light brown crystalline solid. (8.2 g, 90% ) m.p. 115-120 0C, 1H NMR (400 
MHz, CDCl3-d) δ ppm 6.42 (1 H, d, J=8.98 Hz), 7.50 (1 H, dd, J=8.59, 2.34 Hz), 8.11 (1 H, d, 
J=2.34 Hz) 
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5.4.1.2. Synthesis of 2-amino-3-nitro-5-bromopyridine 
 
2-Aminopyridine-5-bromopyridine (2 g, 11.6 mmol) was carefully dissolved in 30 ml of 
H2SO4. The mixture was cooled to 0 
0C. HNO3 (0.8 ml, 11.6 mmol) was added dropwise to the 
stirring solution. The solution was stirred at 0 0C for two hours and heated to 50 0C for another two 
hours. The yellow liquid was poured on to 10 g of crushed ice and a yellow precipitate was filtered 
(2.25 g, 88.9%) m.p. 192-198 0C. 1H NMR (400 MHz, DMSO-d6) δ ppm 8.07 (2 H, s), 8.49 (1 H, 
d, J=2.34 Hz), 8.52 (1 H, d, J=2.34 Hz) 
5.4.1.3. Synthesis of 2,3-diaminopyridine 
 
2-Amino-3-nitro-5-bromopyridine (0.5 g, 2.30 mmol) and Zn dust (0.83g, 12.6 mmol) 
were added to 8 ml of water and 5 ml of methanol. Conc. H2SO4 (0.733 ml 13.76 mmol) was added 
to the suspension and heated at 900 C for 48 hours. The absence of reactants was confirmed by 
TLC. An excess of Na2CO3 was added to the suspension and any solvent present was removed 
under reduced pressure. The product was extracted in methanol. The methanol was removed under 
reduced pressure and the solid obtained was extracted with ethyl acetate. The ethyl acetate was 
dried over MgSO4 and removed under reduced pressure to obtain the product (0.05 g, 20%). m.p. 
92-95 0C  1H NMR (400 MHz, DMSO-d6)  ppm 4.61 (2 H, br. s.), 5.29 (2 H, br. s.), 6.36 (1 H, d, 
J=4.69 Hz), 6.67 (1 H, d, J=7.42 Hz), 7.26 (1 H, d, J=5.08 Hz) 
5.4.1.4. Synthesis of 1-deazapurine 
 
2,3-Diaminopyridine (1.0 g, 9.16 mmol) was mixed with formic acid (0.5 ml, 13.2 mmol). 
The resulting mixture was heated at 170 0C for 48 hours. The excess formic acid was removed 
under reduced pressure and the remaining solid was dissolved in 100 ml water. The product was 
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extracted to ethyl acetate 100 ml X 4. The ethyl acetate was removed under reduced pressure to 
yield the pure product. (0.33g, 30%) m.p. 125-130 0C 1H NMR (400 MHz, DMSO-d6) d ppm 7.23 
(1 H, dd, J=7.81, 4.69 Hz), 8.02 (1 H, d, J=7.81 Hz), 8.35 (1 H, d, J=4.90 Hz), 8.43 (1 H, s), 12.91 
(1 H, br. s.). 
5.4.2. MEP calculations on the donors and acceptors 
5.4.2.1. Calculated MEP values for the 1H and 3H tautomers of 1-Deazapurine 
 AM1/ kJmol-1 DFT 6-31+G*/kJmol-1 
 
3H 
 
1H 
 
3H 
 
1H 
 
Py - N -242 -306 -153 -226 
Im - N -283 -305 -184 -227 
N-H   183 203 259 288 
 
5.4.2.2. Calculated MEP values for the hydrogen-bond and halogen bond donors 
 
Hydrogen-bonddonors AM1/ kJmol-1 DFT 6-31+G*/kJmol-1 
 
144 276 
 
163 295 
 
140 267 
 
137 262 
 
134 267 
 
170 309 
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191(OH) 138 (COOH) 305(OH) 244(COOH) 
 
134 244 
 
176 296 
 
-- 175 
 
-- 182 
 
-- 141 
 
         -- 143 
 
5.4.3. Solvent-drop grinding experiments 
The deazapurine (10 mg 0.083 mmol) was mixed with hydrogen or halogen bond donors 
(0.083 mmol). Two drops of methanol (Hydrogen bond donors) or dichloromethane (halogen bond 
donors) was added to the mixture and ground for two minutes. The solid obtained was analyzed 
by FTIR.   
 
  C=O 930-960 cm-1 Co-crystal 
DA1 
 
1708 953 YES 
DA2 
 
1688 - YES 
DA3 
 
1693 - YES 
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DA4 
 
1693 - YES 
A1 
 
1684 950 YES 
A2 
 
1687 - YES 
A3 
 
1675 951,933 YES 
O1 
 
NA 942 YES 
O2 
 
NA 952 YES 
I1 
 
NA 950 YES 
I2 
 
NA - YES 
I3 
 
NA 953 No 
I4 
 
NA 954 No 
 
5.4.4. Determination of the tautomer based on IR spectroscopy 
Based on the IR spectra of the co-crystals of which the structure has been determined it 
was observed that the stretch at around 950 cm-1 in the deazapurine shifts to around 930 cm-1 in 
all of the structures with the 1H tautomer. No such shift was observed with the structures with 
the 3H tautomer. 
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5.4.5. Syntheses for obtained co-crystals 
5.4.5.1. Synthesis of 1-deazapurine, 1,2-diiodotetrafluorobenzene (1:1), DP:I1 
1-Deazapurine (2.96 mg, 0.025 mmol) and 1,2-diiodotetrafluorobenzene (10 mg, 0.025 
mmol) were dissolved in 2 ml dichloromethane with heat. The solution was allowed to stand at 
room temperature for slow evaporation. Colourless plates were observed in 10 days (m.p.78 – 82 
0C). 
5.4.5.2. Synthesis of 1-deazapurine, 1,4-diiodotetrafluorobenzene (1:1), DP:I2 
1-Ddeazapurine (5 mg, 0.04 mmol) and 1,4-diiodotetrafluorobenzene (16.9 mg, 0.04 
mmol) were dissolved in methanol with heat. The solution was allowed to stand at room 
temperature for slow evaporation. Bronze prisms were observed in two weeks. (m.p. 145 – 149 
0C). 
5.4.5.3. Synthesis of 1-deazapurine, adipic acid (1:1), DP:DA1 
1-Ddeazapurine (10 mg, 0.08 mmol) and adipic acid (12.2 mg, 0.08 mmol) were ground 
together with a drop of methanol. The resulting solid was allowed to crystallize under slow 
evaporation at room temperature. Brown prisms were observed in one week. (m.p. 100 - 104 0C). 
5.4.5.4. Synthesis of 1-deazapurine, sebacic acid (1:1), DP:DA4 
1-deazapurine (10 mg, 0.08 mmol) and sebacic acid (17.0 mg, 0.08 mmol) were ground 
together with a drop of methanol. The resulting solid was allowed to crystallize under slow 
evaporation at room temperature. Colorless prisms were observed in 15 days. (m.p. 80 - 840C). 
 
5.4.5.5. Synthesis of 1-deazapurine, 4-hydroxybenzoic acid (1:1), DP:A4 
1-Deazapurine (10 mg, 0.08 mmol) and 4-hydroxybenzoic acid (11.6 mg, 0.08 mmol) were 
ground together with a drop of methanol. The resulting solid was allowed to crystallize under slow 
evaporation at room temperature. Brown rods were observed in three weeks. (m.p. 165 -170 0C) 
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5.4.6. Structure descriptions 
5.4.6.1. Crystal structure of 1-deazapurine , 1,2-diiodotetrafluorobenzene (1:1), DP:I1 
Structure determination of DP:I1 shows that in the resulting 1:1 co-crystal the deazapurine 
exists in the 3H tautomeric form. The N-H group on the deazapurine picks up the pyridine site of 
another deazapurine molecule forming a homodimer (N13-H13∙∙∙N15 1.97 Å, N13∙∙∙N15 2.843(4) 
Å). The imidazole nitrogen forms a halogen bond to the iodine site on I1 (I1∙∙∙N11 2.800(4) Å) 
resulting in a zero dimensional tetramer. (Figure 5.8) 
 
Figure 5.8 The primary hydrogen-bond interactions in the crystal structure of DP:I1 
 
5.4.6.2. Crystal structure of 1-deazapurine , 1,4-diiodotetrafluorobenzene (1:1), DP:I2 
 
Structure determination of DP:I2 shows that in the resulting 1:1 co-crystal the deazapurine 
exists in the 3H tautomeric form. The N-H group on the deazapurine picks up the pyridine site of 
another deazapurine molecule forming a homodimer (N13-H13∙∙∙N25 1.96 Å, N13∙∙∙N25 2.828(7) 
Å and N23-H23∙∙∙N15 1.99 Å, N15∙∙∙N23 2.848(7) Å). The imidazole nitrogen forms a halogen 
bond to the iodine site (I1∙∙∙N11 2.777(5) Å, I3∙∙∙N21 2.769(5) Å) on I2 forming a one dimensional 
chain.(Figure 5.9) 
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Figure 5.9 The primary hydrogen-bond interactions in the crystal structure of DP:I2 
 
5.4.6.3. Crystal structure of 1-deazapurine , adipic acid (1:1), DP:DA1 
Structure determination of DP:DA1 shows that in the resulting 1:1 co-crystal the 
deazapurine exists in the 3H tautomeric form. The N-H group on deazapurine picks up the pyridine 
site of another deazapurine molecule forming a homodimer (N13-H13∙∙∙N15 1.97(2) Å, N13∙∙∙N15 
2.854(18) Å. The imidazole nitrogen atom is picked up by the carboxylic acid group (O21-
H21∙∙∙N11 170(3) O21∙∙∙N11 2.666(15)) resulting in a one dimensional chain. (Figure 5.10) 
 
Figure 5.10 The primary hydrogen-bond interactions in the crystal structure of DP:DA1. 
5.4.6.4. Crystal structure of 1-deazapurine , sebacic acid (2:1), DP:DA4 
In the case of sebacic acid, a 2:1 co crystal was obtained where the deazapurine exists in 
the 3H tautomer. Instead of the homodimer, the pyridyl nitrogen atom and the N-H group 
deazapurine form a two point interaction with one of the acid groups (N13-H13∙∙∙O22 2.063(19) 
Å, N13∙∙∙O22 2.8624(16) Å) and (O21-H21∙∙∙N15 1.84(2) Å, O21∙∙∙N15 2.6845(16) Å) the second 
acid group picks up the imidazole nitrogen atom of a second deazapurine molecule forming a 
single point interaction. (O30-H30∙∙∙N11 1.86(2) Å, O30∙∙∙N11 2.7603(16) Å) resulting in a one 
dimensional chain.(Figure 5.11) 
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Figure 5.11 The primary hydrogen-bond interactions in the crystal structure of DP:DA4 
5.4.6.5. Crystal structure of 1-deazapurine , 4-hydroxybenzoic acid (1:1), DP:A4 
Structure determination of DP:A4 shows that in the resulting 1:1 co-crystal the 1H tautomer 
is observed where the carboxylic acid group forms a hydrogen-bond to the imidazole nitrogen 
atom (O21-H21∙∙∙N13 1.72(3) Å, O21∙∙∙N13 2.6322(15) Å) and the N-H group on the deazapurine 
hydrogen bonds to a pyridyl nitrogen atom (N11-H11∙∙∙N15   1.97(2) Å, N11∙∙∙N15 2.8506(16) Å).  
The phenol group forms a hydrogen-bond to the carbonyl group on a carboxylic acid group (O24-
H24∙∙∙O22 1.84(3) Å O24∙∙∙O22 2.5961(15) Å) resulting in 2D sheets.(Figure 5.12) 
 
Figure 5.12 The primary hydrogen-bond interactions in the crystal structure of DP:A4 
94 
 
5.5. Discussion 
The synthetic steps for making 1-deazapurine were based on published synthetic methods. 
The bromination of the 5 position of 2-aminopyridine was required as direct nitration almost 
completely yielded 2-amino-5-bromopyridine. Only by blocking the 5 position using the bromo 
group as a protecting group on the pyridine, were we able to obtain the 3-nitro species in significant 
yields. We also combined the reduction of the nitro group and the removal of the Br protecting 
group by hydrodehalogenation in to a single step using Zn as the catalyst and generating H2 in-situ 
using H2SO4. The low yield was due to the photosensitivity of 2,3-diaminopyridine. At the end of 
the reaction no starting material or byproducts were detected by TLC or NMR. This reaction was 
carried out in a closed system under dark conditions. 
The structural data shows that four out of the five structures obtained was of the 3H tautomeric 
form out of which, three formed the deazapurine dimer with the donor group interacting with the 
imidazole nitrogen atom (Figure 5.13 (a)) thus stabilizing the dimer formed between 3H tautomer 
molecules.  
With sebacic acid however, instead of the intended complementary deazapurine dimer a 
similar two- point interaction was observed between the acid and the deazapurine in addition to 
the usual acid imidazole nitrogen interaction (Figure 5.13 (b)). 
 
Figure 5.13 The two supramolecular motifs observed with the 3H tautomer 
The former interaction can be expected as the acid and the 3H tautomer as shown in Figure 
5.14 the two sites are geometrically compatible and the donor site on the acid has a stronger 
hydrogen-bond donating ability compared to the N-H group on the deazapurine. Therefore, sebacic 
acid, which has a higher MEP value, has picked up both acceptor sites on the deazapurine.  
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Figure 5.14 The 3H tautomer of the deazapurine and the acid are geometrically compatible 
IR spectroscopy was used to characterize the formation of co-crystals. Upon comparing IR 
spectra it was observed that the peak at around 930 cm-1 was not found in the IR spectra of any of 
the structures containing the 3H tautomer (Figure 5.15). Although this cannot be observed in all 
cases as some of the donors have broad peaks in the same area, but frequently can be used to 
identify the tautomer present without growing single crystals. 
 
Figure 5.15 IR spectra of 1-deazapurine (red) and the 1:1 co-crystal of  1-
deazapurine:adipic acid (blue) 
Based on calculated MEP values, the hydrogen-bond donor ability of the carboxylic acids 
are greater than that of the N-H group on the deazapurine. The structures obtained with sebacic 
acid and adipic acid (DP:DA3 and DP:DA1) show that using strong two point donor systems like 
carboxylic acids can effectively isolate the 3H tautomer but it can prevent the formation of the 
homomeric deazapurine dimer by forming a heteromeric two-point interaction with the 
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deazapurine (Figure 5.13 (b)). Therefore, even though the desired tautomer is isolated there is no 
structural consistency due to synthon crossover16. In the case of halogen bond donors, the weaker 
halogen bond donors17 are unable to compete with the two point hydrogen bonded dimer and as 
observed in the two structures DP:I1 and DP:I2, will pick up the imidazole nitrogen atom thereby 
stabilizing the self-complementary deazapurine dimer. Therefore halogen bond donors can be used 
stabilize the 3H tautomer without any possibility for synthon crossover.  
5.6. Conclusions 
In conclusion, 1-deazapurine can exist in two prototropic tautomeric forms in aqueous 
solution. Using a selection of hydrogen and halogen bond donors we have successfully isolated 
the 3H tautomer four out of five times by stabilizing complementary dimer formed between the 
deazapurine molecules by forming a hydrogen-bond to the remaining imidazole site on the 
deazapurine. Carboxylic acids have stronger donor group compared to the deazapurine N-H site 
and this can result in it competing for the geometrically compatible pyridine site resulting in 
synthon crossover. This can be prevented by using weaker halogen bond donors that does not 
possess the strength or the geometric bias to compete with the self-complementary homomeric 
deazapurine interaction. Therefore, single-point halogen bond donors can be used to isolate the 3H 
tautomer while maintaining structural consistency. 
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Figure 5.16 Both hydrogen and halogen bond donors can be used to isolate the 3H 
tautomer of 1-deazapurine. 
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Chapter 6. Can urea be used to isolate the 1H tautomer of 1-
deazapurine? 
6.1. Introduction 
6.1.1. Deazapurines 
As discussed in Chapter 5, 1-deazapurine exists in two main tautomeric forms which have 
different supramolecular environments.  The 1H tautomer has two donor sites on the same side of 
the molecule and one acceptor site at the opposite end. A CSD search for possible geometrically 
compatible coformers yielded one promising contender, N,N disubstituted urea with two donor 
sites and a single acceptor site is geometrically compatible to the 1H tautomer of 1-deazapurine. 
Figure 6.1 
 
Figure 6.1 The 1H tautomer of 1-deazapurine is compatible with urea. 
6.1.2. Urea 
The urea functionality has shown considerable importance in pharmaceuticals1,2,3, 
organocatalysts4 self-healing polymers5, supramolecular polymers6 and as selective ion sensors7,8. 
It is also a functional group that has received a great deal of attention in the field of crystal 
engineering9,10,11. 
In almost all of the above cases the functionality and importance of these molecules is 
directly related to the supramolecular behavior of the urea moiety. For example, urea based p38 
MAP kinase inhibitors, which have potential as treatment for Crohn’s disease1 and rheumatoid 
arthritis1, binds to its substrate through a two point hydrogen bond interaction between the urea 
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hydrogen atoms and the carboxylate oxygen atoms of a glutamate group on the substrate, 
incorporation of trisurea groups in polydimethylsiloxane polymers results in a self-healing 
material5 (Figure 6.2 (a)) and in a florescent anion sensor, urea groups act as binding sites for the 
anion7 (Figure 6.2 (b)). 
(a)   
   (b)    
Figure 6.2 (a) homomeric interaction of triurea5 (b) urea based carboxylate sensor7 
In the solid state, N,N-disubstituted ureas form a tape-like network that  involves both N-
H groups forming bifurcated hydrogen bonds to the carbonyl group. This robust synthon, known 
as the α network or α tape is observed in a majority of crystal structure of N,N-disubstituted ureas. 
It has been reported that this synthon persists even in the presence of strong donor groups such as 
carboxylic acids and amides.12  
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Figure 6.3 Donors, acceptors and the α tape motif of N,N-disubstituted urea 
However, the formation of the α tape can be prevented by steric crowding13. In some cases 
such as pyridyl ureas, the urea N-H hydrogen atoms do not form the α tape synthon. Instead, the 
two N-H groups form hydrogen bonds to the pyridyl nitrogen14 (the better acceptor).  
 
      
Figure 6.4 (a) N,N-bistritylurea forms solvates due to steric crowding (b) 1-(4-
chlorophenyl)-3-pyridyl urea forms a N-H•••N interaction instead of the α tape synthon.15 
 
Therefore, it is conceivable that this type of interaction can be used to control the formation 
of the persistent α tape synthon in a multi-component system by controlling the electronic and 
steric environment on the ureas by covalent modification. 
6.1.3. Hypothesis 
 
Figure 6.5 Suggested motif for the co-crystal of the 1H tautomer of 1-deazapurine and urea 
In this chapter, we explore possibility isolating the 1H tautomer of 1 deazapurine with the 
geometrically compatible urea functionality and the effects of changing the electronic and steric 
environment on co-crystal formation (Table 6.1). 
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Table 6.1 Family of ureas with varying donor and acceptor strengths. 
EDG EWG both 
U2  U3  U1  
U6  U4  U5  
U9  U14  U8  
U11  U10  U12  
  U13  U15  
  U7    
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The goals for this chapter are to, 
 Synthesize 1,3-diphenyl urea. 
 Carry out MEP calculations on the deazapurines and the library of ureas. 
 Screen the library of ureas (Table 6.1) against 1-deazapurine.  
 Analyze the screens with IR spectroscopy and X-ray diffraction to detect the formation of 
co-crystals. 
 Isolate the 3H tautomer through co-crystallization. 
6.2. Experimental 
6.2.1. Synthesis of ureas 
6.2.1.1. Synthesis of diphenylurea U1 
Phenylisocyanate (2.14 ml, 19.5 mmol) was dissolved in 10 ml of hexane. Aniline (1.82 
ml, 19.7 mmol) was added dropwise very slowly. The mixture was stirred for one hour. A white 
precipitate was filtered out. (3.90 g, 95%) m.p. 235-239 0C 1H NMR (400 MHz, DMSO-d6)  ppm 
6.92 - 7.01 (2 H, m), 7.22 - 7.31 (4 H, m), 7.44 (4 H, d, J=8.59 Hz), 8.66 (2 H, s) 
6.2.2. MEP calculations 
 
Table 6.2 AM1 and DFT values for the 1H tautomer of 1-deazapurine. 
 AM1/ kJmol-1 DFT 6-31+G*/kJmol-1 
 
1H 
 
1H 
 
Py - N -306 -226 
Im - N -305 -227 
N-H +203 +288 
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Table 6.3 AM1 and DFT values for the library of ureas 
  AM1/ kJmol-1 DFT 6-31+G*/kJmol-1 
  C=O N-H C=O N-H 
U1 
 
-287 198 -162 296 
U2 
 
-308 179 -194 260 
U3 
 
-300 182 -185 269 
U4 
 
-270 215 -148 312 
U5 
 
-326 157 -209 237 
U6 
 
-310 158 -210 226 
U7 
 
-310 186 -203 262 
U8 
 
-306 189 -187 274 
U9 
 
-305 183 -188 260 
U10 
 
-297 198 -177 290 
U11 
 
-312 174 -198 253 
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U12 
 
-299 192 -184 273 
U13 
 
-270 231 -179 311 
U14 
 
-283 211 -165 300 
U15 
 
-269 204 -146 253 
 
6.2.3. Solvent-drop grinding experiments 
The deazapurine (10 mg 0.083 mmol) was mixed with the urea (0.083 mmol). Two drops 
of acetone were added to the mixture and ground for two minutes. The solid obtained was analyzed 
by FTIR.   
6.2.4. IR data from solvent drop grinding experiments 
  C=O 930-960 cm-1 Co-crystal 
U1  1678 939 YES 
U2  1632 953 NO 
U3  1673 942 YES 
U4  1675 935 YES 
U5  1642 950 NO 
U6  1640 951 NO 
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U7  1681 938 YES 
U8  1637 
935 
(U8) NO 
U9  1632 952 NO 
U10  1643 952 NO 
U11  1640 942 NO 
U12  1633 952 NO 
U13  1682 942 YES 
U14  1681 942 YES 
U15  1614 937 YES 
  
Formation of co-crystals was determined by the shifting of the carbonyl peaks of urea. It 
was observed that the stretch at around 950 cm-1 in deazapurine is absent in all cases where the IR 
spectrum of the co-crystals and the stretch at around 930 cm-1 is prominent. 
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Figure 6.6 Co-crystals were identified by the shifting carbonyl peak on the urea(1644 – 
1678 cm-1 for diphenylurea). 
6.2.5. Syntheses of co-crystals 
6.2.5.1. Synthesis of 1-deazapurine diphenylurea (1:1), DP:U1 
1-Deazapurine (10 mg, 0.08 mmol) and  diphenylurea were dissolved in 3 ml of acetone 
with heat. The solution was allowed to stand at room temperature for slow evaporation. Colourless 
needles were observed in three days. (m.p. 170 – 174 C0) 
6.2.5.2. Synthesis of 1-deazapurine 1-(2-cyanophenyl)-3-phenylurea (1:1), DP:U3 
1-Deazapurine (10 mg, 0.08 mmol) and 1-(2-cyanophenyl)-3-phenylurea (8.91 mg 0.04 
mmol) were ground together with a drop of acetone and dissolved in 3 ml methylethylketone with 
heat. The solution was allowed to stand at 0 0C for slow evaporation. Bronze prisms were observed 
in a week. (m.p.120 – 125 0C) 
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6.2.5.3. Synthesis of 1-deazapurine 1-(4-bromophenyl)-3-phenylurea (1:1), DP:U4 
1-Deazapurine (10 mg, 0.08 mmol) and 1-(4-bromophenyl)-3-phenylurea (24.4 mg, 0.08 
mmol) were dissolved in 3 ml acetone and a drop of DMSO with heat. The solution was allowed 
to stand at room temperature for slow evaporation. Colourless plates were observed in two weeks 
(m.p. 165-173 C0) 
6.2.5.4. Synthesis of 1-deazapurine 1-(4-nitrophenyl)-3-(2-tolyl)urea (1:1), DP:U14 
1-Deazapurine (10 mg, 0.08 mmol) and 1-(4-nitrophenyl)-3-(2-tolyl)urea (10.19 mg 0.04 
mmol) were ground together with a drop of acetone and dissolved in a mixture of 3 ml acetone, 1 
ml methanol and 1 ml chloroform with heat. The solution was allowed to stand at 0 0C for slow 
evaporation. Yellow prisms were observed in a week (m.p. 155 -160 C0) 
6.2.5.5. Synthesis of 1-deazapurine  thiourea (1:1), DP:U15 
1-Deazapurine (10 mg, 0.08 mmol) and thiourea (6.09 mg, 0.025 mmol) were dissolved in 
2 ml of methanol with heat. The solution was allowed to stand at room temperature for slow 
evaporation. Gold prisms were observed in two weeks. (m.p. 167 -170 C0) 
 
6.2.6. Structure descriptions 
6.2.6.1. Crystal structure of 1-deazapurine diphenylurea (1:1), DP:U1 
The structure determination of DP:U1 shows that in the resulting 1:1 co-crystal, 
deazapurine exists in the 1H tautomeric form. The two N-H groups of the urea form hydrogen 
bonds to the imidazole (N41-H41∙∙∙N19 1.974(18) Å, N41∙∙∙N19 2.8942(19) Å) and pyridyl (N31-
H31∙∙∙N13 2.196(19) Å, N31∙∙∙N13 3.061(2) Å) nitrogen atoms. The N-H group on the deazapurine 
picks up the carbonyl group (N17-H17∙∙∙O21 Å, 1.81(2) N17∙∙∙O21 2.7508(18) Å) on the urea 
forming a one dimensional chain.(Figure 6.7) 
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Figure 6.7 The primary hydrogen-bond interactions in the crystal structure of DP:U1 
6.2.6.2. Crystal structure of 1-deazapurine 1-(2-cyanophenyl)-3-phenylurea (1:1), 
DP:U3 
In the resulting 1:1 co-crystal of DP:U3 deazapurine exists in the 1H tautomeric form. The 
two N-H groups of the urea form hydrogen bonds to the imidazole (N41-H41∙∙∙N13 2.13(2) Å, 
N41∙∙∙N13 3.040(2) Å) and pyridyl (N31-H31∙∙∙N15 1.98(2) Å, N31∙∙∙N15 2.902(2) Å) nitrogen 
atoms. The N-H group on the deazapurine picks up the carbonyl group on the urea (N11-H11∙∙∙O21 
1.87(2) Å, N11∙∙∙O21 2.799(2) Å) resulting in a one dimensional chain. (Figure 6.8) 
 
 
Figure 6.8 The primary hydrogen-bond interactions in the crystal structure of DP:U3 
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6.2.6.3. Crystal structure of 1-deazapurine  1-(4-bromophenyl)-3-phenylurea (1:1), 
DP:U4 
The structure determination of DP:U4 shows a 1:1 co-crystal, where deazapurine exists in 
the 1H tautomeric form. The two N-H groups of the urea form hydrogen bonds to the imidazole 
(N31-H31∙∙∙N13 2.17(7) Å, N31∙∙∙N13 2.857(6) Å) and pyridyl (N41-H41∙∙∙N15 2.16(7) Å, 
N41∙∙∙N15 3.023(6) Å) nitrogen atoms. The N-H group on the deazapurine picks up the carbonyl 
group on the urea. (N11-H11∙∙∙O21 1.99(7) Å, N11∙∙∙O21 2.701(5) Å) resulting in a one 
dimensional chain.(Figure 6.9) 
 
Figure 6.9 The primary hydrogen-bond interactions in the crystal structure of DP:U4 
6.2.6.4. Crystal structure of 1-deazapurine 1-(4-nitrophenyl)-3-(2-tolyl)urea (1:1), 
DP:U13 
Structure determination of DP:U13 shows that in the resulting 1:1 co-crystal deazapurine 
exists in the 1H tautomeric form. In the two resulting symmetrically inequivalent chains, the two 
N-H groups of the urea form hydrogen bonds to the imidazole (N31_1-H31_1∙∙∙N13_1 2.02(4) Å, 
N31_1∙∙∙N13_1 2.978(4) Å, N31_2-H31_2∙∙∙N13_2 2.08(3) Å, N31_2∙∙∙N13_2 3.005(4) Å) and 
pyridyl (N41_1-H41_1∙∙∙N15_1 Å, 2.02(4) N41_1∙∙∙N15_1 2.994(4) Å, N41_2-H41_2∙∙∙N15_2 
2.08(3) Å, N41_2∙∙∙N15_2 3.024(4) Å) nitrogen atoms. The N-H group on the deazapurine picks 
up the carbonyl group on the urea (N11_1-H11_1∙∙∙O21_2 Å, 1.77(4) N11_1∙∙∙O21_2 2.794 (4) Å 
N11_2-H11_2∙∙∙O21_1 1.85(3) N11_2∙∙∙O21_1 2.803(3) Å). (Figure 6.10) 
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Figure 6.10 The primary hydrogen-bond interactions in the crystal structure of DP:U13 
6.2.6.5. Crystal structure of 1-deazapurine thiourea (1:1), DP:U15 
In the 1:1 co-crystal of DP:U5 deazapurine exists in the 1H tautomeric form. In this 
structure however, the two N-H groups form bifurcated hydrogen bonds to the imidazole nitrogen 
atom N31-H31A∙∙∙N19  2.295(15) Å N31∙∙∙N19  3.0378(12) Å, N41-H41A∙∙∙N19  2.239(16) Å 
N41∙∙∙N19  3.0437(12) Å the N-H group on the deazapurine picks up the pyridyl nitrogen atom 
N17-H17∙∙∙N13 1.980(15) Å N17∙∙∙N13 2.8396(11) Å forming a one dimensional chain.(Figure 
6.11) 
 
Figure 6.11 The primary hydrogen-bond interactions in the crystal structure of DP:U15 
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6.3. Discussion 
All the ureas used in the study were synthesized in a method similar to that shown for 1,3-
diphenyl urea, where the anilines and phenylisocyanates with the desired functional groups were 
combined as shown in section 6.2.1.1. One of the main difficulties experienced in this study was 
in the synthesis of co-crystals as the solubilities of the ureas were significantly lower than that of 
deazapurine, resulting in precipitation of the ureas during slow evaporation. Using asymmetriccaly 
substituted ureas resulted in slightly improved solubility. Best results were observed with acetone 
and methy ethyl ketone and mixtures of these solvents. 
The infrared spectra of the co-crystals obtained with urea (Figure 6.12) show that unlike the 
co-crystals containing the 3H tautomer, where out of two possible peaks at  around 930 cm-1 and 
950 cm-1 only the peak at around 950 cm-1 was observed, in the cases where the 1H tautomer is 
present, only the peak at around 930 cm-1 is present. Both peaks are observed in the synthesized 1-
deazapurine. Even though few data points exist, these peaks maybe useful in predicting which 
tautomer is present witout obtaining single crystal data. 
 
Figure 6.12 Comparing IR spectra of the two tautomers of 1-deazapurine. 
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As seen on Table 6.4, seven out of the fourteen ureas analysed showed evidence of co-crystal 
formation. Out of the seven cases where co-crystal formation has be confirmed by IR spectroscopy, 
five show that the MEPS charges on the carbonyl group on the urea is significantly lower than the 
value on the 1H tautomer of 1-deazapurine. In addition, all  four ureas containing strong electron 
donating groups showed no evidence of co-crystal formation. Out of the six ureas with strong 
electron withdrawing functionalities five formed co crystals. 
 
Table 6.4 Correlating MEP values with synthesized outcomes 
  AM1 DFT  
  C=O N-H C=O N-H Co-crystal 
U1 
 
-287 198 -162 296 
YES 
U2 
 
-308 179 -194 260 
NO 
U3 
 
-300 182 -185 269 
YES 
U4 
 
-270 215 -148 312 
YES 
U5 
 
-326 157 -209 237 
NO 
U6 
 
-310 158 -210 226 
NO 
U7 
 
-310 186 -203 262 
YES 
U8 
 
-306 189 -187 274 
NO 
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U9 
 
-305 183 -188 260 
NO 
U10 
 
-297 198 -177 290 
NO 
U11 
 
-312 174 -198 253 
NO 
U12 
 
-299 192 -184 273 
NO 
U13 
 
-270 231 -179 311 
YES 
U14 
 
-283 211 -165 300 
YES 
U15 
 
-269 204 -146 253 
YES 
The calculated MEP values are consistent with the observed supramolecular outcomes. The 
fact that unsubstituted diphenylurea forms a co-crystal with 1H tautomer of 1-deazapurine tells us 
that the geometric bias of 1H tautomer. Electron-withdrawing substituents enhance co-
crystallization whereas electron-donating substituents prevent co-crystal formation. This is in 
agreement with data published by Etter et. al16,17 where only the ureas with electron withdrawing 
groups except 1,3-di(o-nitrophenyl)ureas resulted in the formation of various co-crystals and  
solvates while the rest of the diarylureas with various substituents consistently formed the urea α 
tape synthon(Table 6.5). This has been explained via a stabilizing intramolecular hydrogen bond 
between the C-H groups ortho to the urea and the carbonyl group.  
 
Table 6.5 Only the diarylureas with electron-withdrawing substituents form co-crystals17 
Compd A B C D E F 
Class I: Diarylureas that will not complex guest acceptors 
1 H H H H H H 
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3α,β H H OCH3 OCH3 H H 
6 OCH3 H H H  OCH3 
7 OCH3 H H H H H 
8 H H OCH3 H H H 
9 H H NO2 NO2 H H 
11 H CH3 H H CH3 H 
Class II: Diarylureas that complex the strong guest acceptors TPPO and/ or DMSO 
4 H NO2 H H H H 
5 H NO2 H H H NO2 
10 NO2 H H H H NO2 
12 H CF3 H H CF3 H 
Class III: Diarylureas that comples strong and moderate acceptors (Ketones, Ethers, 
Nitroanilines) 
2 H NO2 H H NO2 H 
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In all four structures we obtained with the diphenylureas, the two NH groups on the urea pick up 
the pyridyl and imidazole nitrogen atoms on the deazapurine. The N-H group on the deazapurine 
picks up the carbonyl group on the urea. Out of the 14 ureas screened, in five the AM1 charge on 
the carbonyl group was significantly smaller than the charges on the acceptor sites on the 
deazapurine all five of these molecules resulted in co-crystals (Table 6.4). Therefore this system 
too is consistant with Etters rules based on calculated AM1 MEP values. 
 
6.4. Conclusion 
Urea is geometrically compatible with the 1H tautomer of 1-deazapurine and therefore is 
capable of forming co-crystals with this family of molecules disrupting the very robust urea-urea 
α-tape synthon. This is mainly due to the acceptor sites on the deazapurine being significantly 
stronger than the carbonyl group on the urea. Electron donating substituents on the urea increase 
the acceptor ability on the carbonyl group preventing co-crystal formation and electron donating 
groups on the urea further weaken the carbonyl as an acceptor facilitating co-crystal formation. 
 
Figure 6.13 Geometrically compatible urea was successfully used to isolate the 1H tautomer 
of 1-deazapurine. 
 
 
117 
 
References
1 J. Regan, S. Breitfelder, P. Cirillo, T. Gilmore, A. G. Graham, E. Hickey, B. Klaus, J. Madwed, M.Moriak, N. 
Moss, C. Pargellis, S. Pav, A. Proto, A. Swinamer, L. Tong, C. Torcellin, J. Med. Chem. 2002, 45, 2994-3008 
2 Wilson, L. J.; Morris, T. W.; Wu, Q.; Renick, P. J.; Parker, C. N.; Davis, M. C.; McKeever, H. D.; Hershberger, P. 
M.; Switzer, A. G.; Shrum, G. Bioorg. Med. Chem. Lett. 2001, 9, 1149-1152. 
3 J. Baldwin, C. H. Michnoff, N. A. Malmquist, J. White, M. G. Roth, P. K. Rathod and M. A. Phillips, J. Biol. 
Chem., 2005, 280, 21847-21853 
4 A. Berkessel, F. Cleemann, S. Mukherjee, and T. N. Müller, J. Lex, Angew. Chem. Int.Ed., 2005, 44, 807-811 
5 N. Roy, E. Buhler and J. Lehn, Chemistr A European Journal, 2013, 19, 8814-8820 
6 V. Simic, L. Bouteiller, and M. Jalabert J. Am. Chem. Soc., 2003, 125, 43, 13148-13154  
7 T. Gunnlaugsson, A. P. Davis, J. E. O'Brien and M. Glynn, Org. Biomol. Chem., 2005, 3, 48-56 
8 R. Kumar, V. Bhalla and M. Kumar, Tetrahedron, 2008, 64, 8095-8101 
9 C. B. Aakeröy and K. R. Seddon, Chem. Soc. Rev., 1993, 397 
10 M. D. Hollingsworth, Science, 2002, 295, 2410. 
11 G. R. Desiraju, Nature, 2001, 412, 397 
12 X. Zhao, Y.-L. Chang, F. W. Fowler and J. W. Lauher, J. Am. Chem. Soc., 1990, 112, 6627 
13 H. Hart, L. T. W. Lin, D. L. Ward, J. Chem. Soc., Chem. Commun. 1985, 293–294 
14 L. S. Reddy, S. Basavoju, V. R. Vangala, and A. Nangia Cryst. Growth Des., 2006, 6, 161-173,  
15 S. K. Chandran, N. K. Nath, S. Cherukuvada, A. Nangia, Journal of Molecular Structure,  2010, 968, 99–107 
16 M. C. Etter and T. W. Panunto J. Am. Chem. Soc.. 1988, 110, 5897-5898 
17 M. C. Etter, Z. Urbakzyk-Lipkowska, S. M. Zia-Ebrahimi, and T. W. Panunto J. Am. Chem. Soc.. 1990, 112, 
8415-8426 
                                                 
118 
 
Appendix A - NMR Spectra 
 
Figure A.1 1HNMR spectrum of di(H)ox 
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Figure A.2 1HNMR spectrum of di(CH3)ox 
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Figure A.3 1HNMR spectrum of di(Cl)ox 
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Figure A.4 1HNMR spectrum of 1,4-dicyanomethylbenzene 
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Figure A.5 1HNMR spectrum of di(CN)ox 
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Figure A.6 1HNMR spectrum of di(NH2)ox 
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Figure A.7 1HNMR spectrum of ABA 
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Figure A.8 1HNMR spectrum of PhOx 
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Figure A.9 1HNMR spectrum of  4-bromomethylbenzoic acid 
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Figure A.10 1HNMR spectrum of  4-cyanomethylbenzoic acid 
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Figure A.11 1HNMR spectrum of 4BaOx 
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Figure A.12 1HNMR spectrum of  3-bromomethylbenzoic acid 
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Figure A.13 1HNMR spectrum of  3-cyanomethylbenzoic acid 
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Figure A.14 1HNMR spectrum of  3BaOx 
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Figure A.15 1HNMR spectrum of 4PB 
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Figure A.16 1HNMR spectrum of 2-amino-5-bromopyridine 
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Figure A.17  1HNMR spectrum of  2-amino-3-nitro-5-bromopyridine 
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Figure A.18  1HNMR spectrum of 2,3-diaminopyridine. 
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Figure A.19 1HNMR spectrum of 1-deazapurine. 
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Figure A.20  1HNMR spectrum of diphenylurea(U1) 
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Appendix B - Index of abbreviations 
Abbreviation Structure Name 
di(NH2)ox 
 
(1Z,4Z)-N'1,N'4-dihydroxyterephthalimidamide 
di(CH3)ox 
 
(1E,1'E)-1-(4-((E)-1-
(hydroxyimino)ethyl)phenyl)ethanone oxime 
di(H)ox 
 
(1E,1'E)-4-((E)-
(hydroxyimino)methyl)benzaldehyde oxime 
di(Cl)ox 
 
(1Z,4Z)-N'1,N'4-dihydroxyterephthalimidoyl 
dichloride 
di(CN)ox 
 
(1Z,4Z)-N'1,N'4-dihydroxyterephthalimidoyl 
cyanide 
Pz 
 
pyrazine 
Mpz 
 
2,3,5,6-tetramethylpyrazine 
Bp 
 
4,4'-bipyridine 
Bpe 
 
1,2-di(pyridin-4-yl)ethane 
bpe2 
 
(E)-1,2-di(pyridin-4-yl)ethene 
dpp 
 
1,3-di(pyridin-4-yl)propane 
bpo 
 
[4,4'-bipyridine] 1,1'-dioxide 
dbim 
 
1,4-bis((1H-benzo[d]imidazol-1-
yl)methyl)benzene 
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tbim 
 
1,3,5-tris((1H-benzo[d]imidazol-1-
yl)methyl)benzene 
mdpy 
 
1,4-bis((3,5-dimethyl-1H-pyrazol-1-
yl)methyl)benzene 
bdpy 
 
1,4-bis((4-bromo-3,5-dimethyl-1H-pyrazol-1-
yl)methyl)benzene 
dpy 
 
1,4-bis((1H-pyrazol-1-yl)methyl)benzene 
4pp 
  
3bp 
 
phenyl(pyridin-3-yl)methanone 
4bp 
 
phenyl(pyridin-4-yl)methanone 
dcp 
 
3,5-dichloropyridine 
4po 
 
4-methylpyridine 1-oxide 
3po 
 
3-methylpyridine 1-oxide 
35dpb 
 
2,5-dibromopyridine 
3HBA 
 
3-hydroxybenzoic acid 
4HBA 
 
4-hydroxybenzoic acid 
4ABA 
 
(E)-4-((hydroxyimino)methyl)benzoic acid 
140 
 
4BaOx 
 
(Z)-4-(cyano(hydroxyimino)methyl)benzoic acid 
3BaOx 
 
(Z)-3-(cyano(hydroxyimino)methyl)benzoic acid 
4PhOx 
 
(Z)-N,4-dihydroxybenzimidoyl cyanide 
PzO 
 
pyrazine 1-oxide 
MpzO 
 
2,3,5,6-tetramethylpyrazine 1-oxide 
BPO 
 
4,4'-bipyridine 1-oxide 
4PI 
 
4-((2-phenyl-1H-imidazol-1-yl)methyl)pyridine 
3PI 
 
3-((2-phenyl-1H-imidazol-1-yl)methyl)pyridine 
1PB 
 
1-methyl-2-(pyridin-4-yl)-1H-benzo[d]imidazole 
4PB 
 
1-(pyridin-4-ylmethyl)-1H-benzo[d]imidazole 
3PB 
 
1-(pyridin-3-ylmethyl)-1H-benzo[d]imidazole 
4MPB 
 
5,6-dimethyl-1-(pyridin-4-ylmethyl)-1H-
benzo[d]imidazole 
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3MPB 
 
5,6-dimethyl-1-(pyridin-3-ylmethyl)-1H-
benzo[d]imidazole 
U1  
1,3-diphenylurea 
U2  
1-phenyl-3-(o-tolyl)urea 
U3  
1-(2-cyanophenyl)-3-phenylurea 
U4  
1-(4-bromophenyl)-3-phenylurea 
U5  
1-(2-chlorophenyl)-3-(o-tolyl)urea 
U6  
1-(2-methoxyphenyl)-3-(o-tolyl)urea 
U7  
1-(2-nitrophenyl)-3-(o-tolyl)urea 
U8  
1-(3-chlorophenyl)-3-(o-tolyl)urea 
U9  
1-(3-methoxyphenyl)-3-(o-tolyl)urea 
U10  
1-(3-cyanophenyl)-3-(o-tolyl)urea 
U11  
1-(4-methoxyphenyl)-3-(o-tolyl)urea 
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U12  
1-(4-chlorophenyl)-3-(o-tolyl)urea 
U13  
1-(4-nitrophenyl)-3-(o-tolyl)urea 
U14  
1-(4-cyanophenyl)-3-(o-tolyl)urea 
U15  
Thiourea 
 
 
